


# MIND MAPS IN CLINICAL CHEMISTRY

FOR CORE COMPETENCIES IN LABORATORY  
DIAGNOSTICS



**Simmi Kharb**

**Bentham Books**

# **Mind Maps in Clinical Chemistry for Core Competencies in Laboratory Diagnostics**

Authored by

**Simmi Kharb**

*Department of Biochemistry*

*Pt. B.D. Sharma Post Graduate Institute of Medical Sciences  
(PGIMS)*

*Rohtak 124001, Haryana, India*

**O kpf 'O cru'k'EnpkcnEj go km { 'hqt 'Eqg'  
Eqo rgvpekgu'lp'Ncdqt cvqt { 'F ki pqvku'**

Author: Simmi Kharb

ISBN (Online): 979-8-89881-651-3

ISBN (Print): 979-8-89881-652-0

ISBN (Paperback): 979-8-89881-653-7

© 2026, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore,  
in collaboration with Eureka Conferences, USA. All Rights Reserved.

First published in 2026.

## **BENTHAM SCIENCE PUBLISHERS LTD.**

### **End User License Agreement (for non-institutional, personal use)**

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [permission@benthamscience.org](mailto:permission@benthamscience.org).

### **Usage Rules:**

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

### ***Disclaimer:***

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

### ***Limitation of Liability:***

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

### **General:**

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

**Bentham Science Publishers Pte. Ltd.**

No. 9 Raffles Place

Office No. 26-01

Singapore 048619

Singapore

Email: [subscriptions@benthamscience.net](mailto:subscriptions@benthamscience.net)



## CONTENTS

PREFACE .....	i
<b>CHAPTER 1 DISORDERS OF ACID-BASE AND PULMONARY FUNCTION</b> .....	1
<b>LEARNING OBJECTIVES</b> .....	1
<b>KEY CONCEPTS</b> .....	1
Acid-base balance and pulmonary functions [1,2] .....	1
<i>Acid-base balance</i> .....	1
<i>Acid-base homeostasis</i> .....	2
<i>Buffer</i> .....	2
<i>Buffer systems and various organs maintain extracellular pH</i> .....	2
<i>Buffers</i> .....	2
<i>Renal compensation</i> .....	3
<i>Regulation of pH by lungs</i> .....	3
<b>CAUSES, CLINICAL SIGNS, AND SYMPTOMS OF THE DISORDERS RELATING TO ACID-BASE BALANCE AND PULMONARY FUNCTION</b> .....	5
Imbalance of acid-base .....	5
<i>Types</i> .....	5
<b>COMPENSATORY MECHANISM FOR MAINTAINING BALANCED BLOOD PH</b> .....	6
Acid-base imbalances overcome the buffer system .....	6
<i>At the level of the lungs</i> .....	6
<i>At the level of the kidneys</i> .....	6
<i>Mechanism</i> .....	6
<i>During acidosis</i> .....	6
<i>During alkalosis</i> .....	7
<b>BUFFER SYSTEMS IN THE HUMAN BODY</b> .....	7
BICARBONATE (HCO <sub>3</sub> <sup>-</sup> ) .....	7
<i>Sources of CO<sub>2</sub> in the body</i> .....	8
<i>At the renal level</i> .....	9
<i>At the level of the lungs</i> .....	9
<b>PH OF THE HUMAN BODY AVERAGES AT 7.40</b> .....	10
Counterbalance homeostasis in acid-base disorders .....	10
Phosphate buffer system .....	11
<i>Urine buffers</i> .....	11
<i>Ammonia excretion</i> .....	11
<i>Protein buffers</i> .....	11
<i>Role of erythrocytes and haemoglobin in the acid-base balance</i> .....	12
<i>Organ systems involved in acid-base balance [3,4]</i> .....	12
<b>LABORATORY INVESTIGATIONS THAT ARE IMPORTANT IN THEIR DETECTION, DIAGNOSIS, AND MANAGEMENT</b> .....	13
Related Testing .....	13
1. <i>Arterial Blood Gas (ABG) sampling</i> .....	13
2. <i>Other tests</i> .....	13
<i>Anion gap</i> .....	13
<i>Formula</i> .....	14
<i>Use</i> .....	14
<i>Elevated anion gap metabolic acidosis</i> .....	14
<i>Compensation for Acidosis and Alkalosis</i> .....	15
<i>Compensation</i> .....	15
<i>Control of respiration<sup>3</sup></i> .....	15
<i>Medullary inspiratory centre</i> .....	15

<i>Pneumotoxic area</i> .....	16
<i>Apneustic area</i> .....	16
<i>Chemoreceptors and respiratory centres</i> .....	16
<i>Central chemoreceptors</i> .....	16
<i>Entry of plasma CO<sub>2</sub> in CSF</i> .....	16
<i>Increase in pH or pCO<sub>2</sub>, or a decrease in pO<sub>2</sub></i> .....	16
<i>Chemoreceptor regulation of breathing</i> .....	17
<i>Henderson-Hasselbach equation</i> .....	17
Hemoglobin dissociation curves and calculated oxygen saturation .....	18
.....	18
<i>Osmole</i> .....	18
<i>Osmolality of a solution</i> .....	18
<i>Osmolarity of a solution</i> .....	18
<i>Calculated osmolarity</i> .....	19
<i>Osmolar gap</i> .....	19
<i>Types of Osmometers</i> .....	19
<i>Elevated osmolar gap indicates an unknown solute, but does not identify it</i> .....	20
<i>Systematic approach to investigating acid-base disturbances<sup>4</sup></i> .....	20
<b>DISEASES</b> .....	22
Alpha-1 Antitrypsin (A1AT) deficiency .....	22
Carbon monoxide poisoning .....	25
Metabolic acidosis .....	26
Metabolic alkalosis .....	27
Pyloric stenosis .....	28
Renal tubular acidosis (also refer to disorders of the kidney and urinary tract) .....	28
Respiratory acidosis .....	30
<b>LABORATORY INVESTIGATIONS AND INTERPRET ANALYTICAL RESULTS</b>	
<b>(TABLE 2)</b> .....	30
Summary .....	31
Exercises .....	32
<b>CONCLUSION</b> .....	32
<b>ACKNOWLEDGEMENT AND CONFLICT OF INTEREST</b> .....	32
<b>REFERENCES</b> .....	32
<b>CHAPTER 2 CANCER</b> .....	33
<b>LEARNING OBJECTIVES</b> .....	33
<b>KEY CONCEPTS</b> .....	33
Biochemical Aspects of Monitoring Malignant Disease [1 - 5] .....	33
<b>KEY BIOCHEMICAL ASPECTS COMMONLY MONITORED IN MALIGNANT</b>	
<b>DISEASES: [3, 4]</b> .....	36
Tumor Markers .....	36
<i>Definition</i> .....	36
<i>Application</i> .....	36
Genetic Biomarkers .....	36
Metabolic Markers .....	36
<i>Techniques</i> .....	37
<i>Application</i> .....	37
Inflammatory Markers .....	37
<i>Application</i> .....	37
Hormonal Markers .....	37
Drug Levels and Metabolites .....	37

Immune Markers .....	38
Oncogenic Signaling Pathways .....	38
<b>KEY CONCEPTS RELATING TO CHOICE, USE, AND MEASUREMENT OF BIOMARKERS OF MALIGNANCY [3, 4, 6] .....</b>	<b>38</b>
<b>KEY CONCEPTS RELATING TO THE SELECTION, UTILIZATION, AND MEASUREMENT OF BIOMARKERS IN MALIGNANCY .....</b>	<b>40</b>
Ideal Tumor/Cancer Biomarkers .....	40
<b>USES AND LIMITATIONS OF CURRENT BIOMARKERS OF CANCER .....</b>	<b>41</b>
<b>USES OF BIOMARKERS OF CANCER: PROGNOSIS, MONITORING, AND RECURRENCE .....</b>	<b>42</b>
<b>SPECIFIC LABORATORY INVESTIGATIONS IN THE MANAGEMENT OF MALIGNANT DISEASES .....</b>	<b>43</b>
<b>LABORATORY INVESTIGATIONS IN THE MANAGEMENT OF MALIGNANT DISEASES .....</b>	<b>44</b>
<b>LAB INVESTIGATIONS FOR MANAGEMENT OF MALIGNANT DISEASES .....</b>	<b>45</b>
Analytical Methods Available for the Measurement of Biomarkers of Cancer .....	45
<b>ANALYTICAL METHODS USED FOR MEASURING BIOMARKERS OF CANCER .....</b>	<b>47</b>
<b>INTERPRET THE ANALYTICAL RESULTS IN THE CONTEXT OF THE CLINICAL SIGNS AND SYMPTOMS [6 - 8] .....</b>	<b>48</b>
AFP .....	48
<i>AFP Levels</i> .....	48
ALP Isoenzymes .....	49
<i>Occurrence</i> .....	49
<i>Total ALP Level</i> .....	49
<i>ALP Isoenzymes</i> .....	49
<i>Liver ALP (ALP-L)</i> .....	49
<i>Bone ALP (ALP-B)</i> .....	49
<i>Intestinal ALP (ALP-I)</i> .....	50
<i>Imaging Studies</i> .....	50
<i>Additional Laboratory Tests</i> .....	50
CA 15-3 .....	50
CA 19-9 .....	51
<i>Normal Reference Range</i> .....	52
<i>Pancreatic Cancer</i> .....	52
<i>Other Gastrointestinal Cancers</i> .....	52
<i>Benign Conditions</i> .....	52
CA 125 .....	53
<i>Ovarian Cancer</i> .....	53
<i>Other Gynecological Malignancies</i> .....	53
<i>Benign Gynecological Conditions</i> .....	53
CA 27-29 .....	53
Normal Reference Range .....	54
Breast Cancer .....	54
Calcitonin .....	54
<i>Normal Reference Range</i> .....	54
<i>Medullary Thyroid Carcinoma (MTC)</i> .....	54
<i>Thyroid Nodules</i> .....	55
CEA .....	55
Normal Reference Range .....	55
Elevated levels .....	55
HE4 .....	56

<i>Normal Reference Range</i> .....	56
<i>Elevated HE4</i> .....	56
hCG .....	56
<i>Normal reference range</i> .....	56
<i>Elevated levels</i> .....	57
HER2/Neu .....	57
<i>Elevated levels</i> .....	57
LDH Isoenzymes .....	58
<i>Elevated levels</i> .....	58
<i>Elevated LDH Isoenzyme Levels</i> .....	58
Mammary-Specific Antigen .....	59
<i>Normal reference range</i> .....	59
Elevated MSA levels .....	59
<i>Breast Cancer Screening</i> .....	59
PSA (Total and Free) .....	60
<i>Normal PSA Levels</i> .....	60
<i>Elevated PSA Levels</i> .....	60
<b>PTHrP</b> .....	60
Normal reference range .....	60
<i>Elevated PTHrP</i> .....	61
<b>PROTEIN ELECTROPHORESIS</b> .....	61
Normal protein fractions .....	61
<i>Elevated levels</i> .....	62
<i>Interpretation of Results</i> .....	62
Thyroglobulin, Anti-Thyroglobulin Antibodies .....	63
<i>Normal reference ranges</i> .....	63
<i>Elevated Thyroglobulin (Tg)</i> .....	63
Other Emerging Biomarkers .....	64
<i>Interpretation of Results</i> .....	64
<i>Clinical context</i> .....	64
<i>Consult</i> .....	65
<b>EMERGING BIOMARKERS IN CANCER RESEARCH</b> .....	66
Summary .....	66
Exercises .....	66
<b>CONCLUSION</b> .....	67
<b>REFERENCES</b> .....	67
<b>CHAPTER 3 CARDIOVASCULAR DISORDERS AND HYPERTENSION DISEASES</b> .....	68
<b>LEARNING OBJECTIVES</b> .....	68
<b>KEY CONCEPTS</b> .....	68
Acute Coronary Syndrome .....	68
<i>Acute Coronary Syndrome (ACS) [1]</i> .....	68
<i>Biochemical Basis</i> .....	69
<i>Causes of ACS</i> .....	70
<i>Clinical Signs and Symptoms of Acute Coronary Syndrome</i> .....	70
<b>KEY CONCEPTS: BIOCHEMICAL BASIS OF CAUSES AND CLINICAL SIGNS AND SYMPTOMS OF ACS</b> .....	70
Key Concepts: Biochemical Changes of Disease or Disorder .....	70
<b>LABORATORY INVESTIGATIONS FOR DETECTION, DIAGNOSIS, AND MANAGEMENT</b> .....	72
Cardiac Risk Assessment1-4 .....	72

<i>Assessment Tools</i> .....	74
Myocardial Infarct .....	75
<i>Biochemical changes in myocardial infarction [1]</i> .....	75
<b>CONDITIONS</b> .....	77
Relevant Laboratory Tests, Analytics Methods Available and Applied Aspects .....	77
Atherosclerosis .....	77
<i>Relevant Laboratory Tests for Detection, Diagnosis, Management, and Monitoring are Mentioned in Table 5</i> .....	77
Cardiac amyloid .....	79
<i>Relevant Laboratory Tests for Detection, Diagnosis, Management, and Monitoring are presented in Table 6</i> .....	79
Congestive Heart Failure .....	80
<i>Relevant Laboratory Tests for Detection, Diagnosis, Management, and Monitoring are presented in Table 7.</i> .....	80
4. Hypertension <sup>4</sup> .....	82
<i>Relevant Laboratory Tests for Detection, Diagnosis, Management, and Monitoring are presented in Table 8</i> .....	82
Myocardial infarction [1] .....	83
<i>Relevant Laboratory Tests for Detection, Diagnosis, Management, and Monitoring are presented in Table 9</i> .....	83
Stable angina .....	85
<i>Relevant Laboratory Tests for Detection, Diagnosis, Management, and Monitoring are presented in Table 10</i> .....	85
Unstable angina .....	87
<i>Relevant Laboratory Tests for Detection, Diagnosis, Management, and Monitoring are presented in Table 11</i> .....	87
<b>RELEVANT LABORATORY TESTS, ANALYTICS METHODS AVAILABLE AND APPLIED ASPECTS</b> .....	89
High-sensitivity CRP Table 12 .....	89
<i>Relevant laboratory tests, analytics methods available, and applied aspects</i> .....	89
Natriuretic peptides Table 13 .....	89
<i>Relevant laboratory tests, analytics methods available and applied aspects</i> .....	89
Serum and urine electrophoresis and immunoglobulins Table 14 .....	89
<i>Relevant laboratory tests, analytics methods available, and applied aspects</i> .....	90
Troponin and high-sensitivity troponin (Table 15, Fig. 1) .....	90
<i>Relevant laboratory tests, analytics methods available and applied aspects</i> .....	91
<i>Use and limitations of testing strategies/algorithms for cardiac markers Table 16 [4]</i> .....	91
Summary .....	91
Exercises .....	91
<b>CONCLUSION</b> .....	92
<b>REFERENCES</b> .....	92
<b>CHAPTER 4 DIABETES MELLITUS</b> .....	94
<b>LEARNING OBJECTIVES</b> .....	94
<b>KEY CONCEPTS: PATHOGENESIS OF DIABETIC STATES AND REGULATION OF GLUCOSE HOMEOSTASIS</b> .....	94
Pathogenesis of Diabetic States and the Applied Aspects of the Study of Diabetes Mellitus (Table 1) [1] .....	94
<b>KEY CONCEPTS: DYSREGULATION OF GLUCOSE HOMEOSTASIS IN DIABETES MELLITUS</b> .....	96

Causes, Clinical Signs and Symptoms of Applied Aspects of Diabetes Mellitus (Table 2). [1 - 3]	96
<b>KEY CONCEPTS: ETIOLOGY OF TYPE I, TYPE 2, AND GESTATIONAL DIABETES (TABLE 3)</b>	97
<b>KEY CONCEPTS: DIABETES, COMPLICATIONS AND CLINICAL MANAGEMENT (TABLE 4) [1, 5,6]</b>	98
<b>BIOCHEMICAL BASIS, RELEVANT LAB TESTS, INTERPRETATION OF RESULTS, AND APPLIED ASPECTS</b>	99
Laboratory Investigations that are Important in the Detection, Diagnosis, and Management of Complications (Table 5). [2, 6]	99
<b>RELEVANT LABORATORY TESTS, ANALYTICS METHODS AVAILABLE AND APPLIED ASPECTS (TABLE 5, FIG. (1-3): [2]</b>	101
Summary	104
Exercises	104
<b>CONCLUSION</b>	105
<b>REFERENCES</b>	105
<b>CHAPTER 5 DISORDERS OF THE KIDNEY AND URINARY TRACT</b>	108
<b>KEY CONCEPTS</b>	109
KEY CONCEPTS: Normal Renal Function	109
<i>Principles and Control of Renal Function (Table 1-3) [1-4]</i>	109
<b>CLINICAL INTERVENTIONS THAT SUPPLEMENT/REPLACE DECLINING RENAL FUNCTION (TABLE 4-8) [1-3]</b>	111
<b>BIOCHEMICAL BASIS, RELEVANT LAB TESTS, INTERPRETATION OF RESULTS, AND APPLIED ASPECTS</b>	115
Laboratory Investigations are Important in their Detection, Diagnosis, and Management (Table 9-10)	115
<i>Specialized Tests</i>	119
<b>ANALYTICAL METHODS</b>	119
Analytical Methods Available for Measurement (Table 11-13)	119
<b>BIOCHEMICAL BASIS, RELEVANT LAB TESTS, INTERPRETATION, AND APPLIED ASPECTS: URINARY TRACT</b>	122
Laboratory Investigations and Interpret the Analytical Results in the Context of Clinical Signs and Symptoms (Table 12-15, 16) [1-4]	122
<b>ANALYTICAL METHODS FOR URINARY TRACT TESTS</b>	125
Relevant Laboratory Tests for Uric Acid Metabolism	125
Relevant Laboratory Tests for Detection, Diagnosis, Management, and Monitoring: Renal and Related Disorders	125
Summary	125
Exercises	125
<b>CONCLUSION</b>	126
<b>REFERENCES</b>	126
<b>CHAPTER 6 ENDOCRINOLOGY</b>	127
<b>LEARNING OBJECTIVES</b>	127
<b>KEY CONCEPTS: HORMONE ACTION</b>	127
Hormone Action and Regulation (Table 1,2) [1 - 3]	127
<b>KEY CONCEPTS: HYPOTHALAMIC- PITUITARY AXIS</b>	129
<b>BIOCHEMICAL BASIS, RELEVANT LAB TESTS, INTERPRETATION, AND APPLIED ASPECTS: ENDOCRINE DISORDERS</b>	130
Causes, Clinical Presentation, and Laboratory Diagnosis of Endocrine Disorders (Table 3). [1 - 4]	130

<b>RELEVANT LABORATORY TESTS FOR DETECTION, DIAGNOSIS, MANAGEMENT, AND MONITORING</b> .....	132
Relevance of Laboratory Investigations in Detection, Diagnosis, and Management of Endocrine Disorders (Table 4). [1 - 3] .....	132
<b>RELEVANT LABORATORY TESTS, INTERPRETATION OF ANALYTICAL RESULTS, AND ANALYTICAL METHODS</b> .....	134
Laboratory Investigations and Interpretation of Analytical Results in the Context of the Clinical Signs and Symptoms (Table 5). [1 - 5] .....	134
<b>SUMMARY</b> .....	136
<b>EXERCISES</b> .....	136
<b>CONCLUSION</b> .....	136
<b>REFERENCES</b> .....	137
<b>CHAPTER 7 FLUID AND ELECTROLYTE DISORDERS</b> .....	138
<b>KEY CONCEPTS</b> .....	138
Basic Concept and Homeostasis Of Fluid And Electrolyte Balance .....	138
<i>Physiological Mechanisms Regulating Fluid And Electrolyte Balance (Table 1) [1-3]</i> .....	138
<b>APPLIED ASPECTS OF HOMEOSTASIS OF FLUID AND ELECTROLYTE BALANCE</b> .....	141
Causes and Consequences of Fluid and Electrolyte Disorders (Table 2) .....	141
<b>KEY CONCEPTS: EXTRACELLULAR AND INTRACELLULAR FLUID VOLUMES</b> ....	142
Laboratory Tests Used To Diagnose Fluid And Electrolyte Imbalances (Table 3-5) [1-4] ...	142
<b>APPLIED ASPECTS OF EXTRACELLULAR AND INTRACELLULAR FLUID VOLUMES</b> .....	143
<b>APPLIED ASPECTS OF CLINICAL ASSESSMENT OF EXTRACELLULAR FLUID (ECF) VOLUME</b> .....	143
Key Concepts Of Hormonal Control Of Fluid And Electrolyte Balance .....	145
<i>Clinical Knowledge To Interpret Laboratory Results In The Context of Patient Symptoms (Table 6, 7) [1-4]</i> .....	145
<b>APPLIED ASPECTS OF HORMONAL CONTROL OF FLUID AND ELECTROLYTE BALANCE</b> .....	145
Impact of Fluid And Electrolyte Disorders On Overall Health And Disease Outcomes (Table 8-11) .....	145
<b>BIOCHEMICAL BASIS, RELEVANT LAB TESTS, INTERPRETATION, AND APPLIED ASPECTS: DISORDERS OF FLUID AND ELECTROLYTE BALANCE</b> .....	147
Biochemical Basis, Relevant Lab Tests, Analytical Methods, Interpretation and Applied Aspects (Table 12, 13) [1-4] .....	147
<b>RELEVANT LABORATORY TESTS, ANALYTICS METHODS AVAILABLE AND APPLIED ASPECTS</b> .....	148
Summary .....	148
<b>EXERCISES</b> .....	149
<b>CONCLUSION</b> .....	150
<b>REFERENCES</b> .....	150
<b>CHAPTER 8 GASTROINTESTINAL AND PANCREATIC DISEASE</b> .....	151
<b>LEARNING OBJECTIVES</b> .....	151
<b>KEY CONCEPTS: GASTROINTESTINAL AND PANCREATIC SYSTEMS</b> .....	151
Functions of the Gastrointestinal and Pancreatic Systems (Table 1-4; Fig. 1, Fig. 2). [1, 2] .....	151
<b>KEY CONCEPTS: INTESTINAL ABSORPTION OF PROTEINS, FATS, AND CARBOHYDRATES</b> .....	152
<b>KEY CONCEPTS: ENDOCRINE AND EXOCRINE FUNCTIONS OF THE PANCREAS [3, 4]</b> .....	153
<b>KEY CONCEPTS: VITAMIN B12 ABSORPTION</b> .....	156

Biochemical Basis, Relevant LAB Tests, Interpretation, and Applied Aspects .....	156
<i>Laboratory Investigations in Detection, Diagnosis, and Management of</i>	
<i>Gastrointestinal and Pancreatic Diseases (Table 5, 6) [1 - 4]</i> .....	156
<b>RELEVANT LABORATORY TESTS FOR DETECTION, DIAGNOSIS, MANAGEMENT,</b>	
<b>AND MONITORING</b> .....	159
Relevant Laboratory Tests, Analytics Methods Available and Applied Aspects .....	159
<i>Analytical Methods Available for their Measurement (Table 7)</i> .....	159
<b>SUMMARY</b> .....	162
<b>EXERCISE</b> .....	162
<b>CONCLUSION</b> .....	163
<b>REFERENCES</b> .....	163
<b>CHAPTER 9 HEPATOBILIARY DISEASE</b> .....	164
<b>LEARNING OBJECTIVES</b> .....	164
<b>KEY CONCEPTS: METABOLIC FUNCTIONS OF THE LIVER</b> .....	165
Physiological and Biochemical Functions of Hepatobiliary System (Tables 1, 2) [1-4] .....	165
<b>KEY CONCEPTS: ORIGIN, METABOLISM, AND TRANSPORT OF BILIRUBIN</b> .....	165
Biochemical Basis, Relevant Lab Tests, Interpretation, and Applied Aspects .....	165
<i>Biochemical Aspects of Hepatobiliary Disease</i> .....	165
Biochemical basis, relevant lab tests, interpretation, and applied aspects .....	169
<i>Biochemical basis of hepatobiliary disease</i> .....	169
Biochemical basis, relevant lab tests, interpretation, and applied aspects: liver conditions ...	170
<i>Relevant laboratory tests, analytical methods available</i> .....	170
<b>SUMMARY</b> .....	172
<b>EXERCISES</b> .....	172
<b>CONCLUSION</b> .....	172
<b>REFERENCES</b> .....	173
<b>CHAPTER 10 IMMUNOLOGY</b> .....	174
<b>LEARNING OBJECTIVES</b> .....	174
<b>KEY CONCEPTS: BASICS, COMPONENTS, AND CONTROL OF THE IMMUNE</b>	
<b>SYSTEM</b> .....	174
Principles, Components and Control of the Immune System (Tables 1-4) [1 - 4] .....	174
<b>KEY CONCEPTS: COMPONENTS OF IMMUNE SYSTEM: CELLS, LYMPHOID</b>	
<b>TISSUE, SOLUBLE COMPONENTS, AND MEDIATORS</b> .....	175
<b>KEY CONCEPTS: IMMUNE CELLS</b> .....	176
<b>KEY CONCEPTS: IMMUNOGLOBULIN PRODUCTION, STRUCTURE, AND</b>	
<b>FUNCTION</b> .....	177
<b>KEY CONCEPTS: LABORATORY INVESTIGATIONS IN DETECTION, DIAGNOSIS</b>	
<b>AND MANAGEMENT (TABLE 5.1,5.2; 6,-11)</b> .....	178
<b>KEY CONCEPTS: PRINCIPLES OF CELLULAR IMMUNITY, HUMORAL IMMUNITY</b>	
<b>AND INFLAMMATORY REACTIONS</b> .....	179
<b>KEY CONCEPTS: COMPLEMENT SYSTEM</b> .....	179
<b>KEY CONCEPTS: CYTOKINES:</b> .....	180
<b>KEY CONCEPTS: HYPERSENSITIVITY REACTION TYPES I – IV (OR V):</b> .....	181
<b>KEY CONCEPTS: IMMUNOGLOBULINS</b> .....	182
<b>KEY CONCEPTS: INNATE IMMUNE SYSTEM</b> .....	182
<b>BIOCHEMICAL BASIS, RELEVANT LAB TESTS, INTERPRETATION, AND APPLIED</b>	
<b>ASPECTS</b> .....	183
Laboratory Investigations and Interpretation of Analytical Results in the Context of Clinical	
Signs and Symptoms (Tables 12,13.1, 13.2) [1 - 4] .....	183
Relevant laboratory tests for detection, diagnosis, management, and monitoring .....	185

Relevant laboratory tests, analytics methods available, and applied aspects .....	186
<b>SUMMARY</b> .....	188
<b>EXERCISES</b> .....	188
<b>CONCLUSION</b> .....	189
<b>REFERENCES</b> .....	189
<b>CHAPTER 11 INBORN ERRORS OF METABOLISM</b> .....	190
<b>LEARNING OBJECTIVES</b> .....	190
<b>KEY CONCEPTS: CHALLENGES WITH NEWBORN SCREENING.</b> .....	190
Biochemical Basis and Pathophysiology of Common Inborn Errors of Metabolism (IEMs) (Table 1) [1 - 4] .....	190
<b>KEY CONCEPTS: DISEASES APPROPRIATE FOR NEWBORN SCREENING –     CHARACTERISTICS (TABLE 2)</b> .....	191
<b>BIOCHEMICAL BASIS, RELEVANT LAB TESTS, INTERPRETATION, AND APPLIED     ASPECTS</b> .....	192
Role of Laboratory Tests in Diagnosis, Monitoring, and Management of IEMs (Tables 3,4) [1 - 4] .....	192
<i>Relevant laboratory tests, analytics methods available, and applied aspects</i> .....	194
<b>SUMMARY</b> .....	195
<b>EXERCISES</b> .....	195
<b>CONCLUSION</b> .....	195
<b>REFERENCES</b> .....	196
<b>CHAPTER 12 INFECTIOUS DISEASES</b> .....	197
<b>LEARNING OBJECTIVES</b> .....	197
<b>KEY CONCEPTS ROLE OF LABORATORY AND SEROLOGY TESTING IN     DIAGNOSIS AND MONITORING OF INFECTIOUS DISEASE:</b> .....	197
Role of Laboratory Testing in Diagnosis and Monitoring of Infectious Diseases (Tables 1,2) [1, 2] .....	197
<b>DISEASE</b> .....	198
Relevant Laboratory Tests for Infectious Diseases for Detection, Diagnosis, Management, or Monitoring .....	198
<b>RELEVANT LABORATORY TESTS FOR DETECTION, DIAGNOSIS, MANAGEMENT,     OR MONITORING AND ANALYTICS METHODS AVAILABLE</b> .....	200
Recommendation and Interpretation of Laboratory Tests for the Diagnosis and Management of the Infectious Diseases (Tables 3,4) [1 - 5] .....	200
<b>RELEVANT LABORATORY TESTS FOR DETECTION, DIAGNOSIS, AND     MANAGEMENT, OR MONITORING ANALYTICS METHODS AVAILABLE AND     APPLIED TO ASPECTS OF INFECTIOUS DISEASES</b> .....	202
<b>SUMMARY</b> .....	203
<b>EXERCISES</b> .....	203
<b>CONCLUSION</b> .....	204
<b>REFERENCES</b> .....	204
<b>CHAPTER 13 IRON AND HEMOGLOBIN DISORDERS, INCLUDING PORPHYRIAS</b> .....	205
<b>LEARNING OBJECTIVES</b> .....	205
<b>KEY CONCEPTS: IRON AND HEME METABOLISM AND THEIR REGULATION</b> .....	206
Regulation of Iron Absorption, Transport, Storage, and its Role in Hemoglobin Synthesis (Tables 1-3.1, 3.2) [1-5] .....	206
<b>KEY CONCEPTS: APPLIED ASPECTS OF IRON AND HEME METABOLISM</b> .....	206
<b>KEY CONCEPTS: BIOCHEMICAL BASIS OF IRON OVERLOAD AND IRON     DEFICIENCY</b> .....	207

Implications of iron overload and iron deficiency .....	207
<b>KEY CONCEPTS: APPLIED ASPECTS OF ENZYMATIC DEFECTS OF HEME</b>	
<b>SYNTHESIS (LEADING TO PORPHYRIAS)</b> .....	208
Biochemistry of Porphyrins: Biochemical Basis of Porphyrins and their Clinical	
Implications (Tables 4-5) [3] .....	208
<b>KEY CONCEPTS: TYPES OF PORPHYRIAS AND THEIR BIOCHEMICAL BASIS</b> .....	209
Biochemical basis, relevant lab tests, interpretation, and applied aspects .....	209
<i>Interpretation of Laboratory Tests Related to Iron Metabolism, Hemoglobin</i>	
<i>Disorders, and Porphyrins (Tables 6-8; Fig. 1) [1, 3, 5]</i> .....	209
<i>Relevant laboratory tests for detection, diagnosis, management, and monitoring</i> .....	211
<i>Biochemical basis, relevant lab tests, interpretation, and applied aspects</i> .....	212
<b>SUMMARY</b> .....	213
<b>EXERCISES</b> .....	214
<b>CONCLUSION</b> .....	214
<b>REFERENCES</b> .....	214
<b>CHAPTER 14 LIPIDS AND DISORDERS OF LIPOPROTEIN METABOLISM</b> .....	215
<b>LEARNING OBJECTIVES</b> .....	215
<b>KEY CONCEPTS: LIPID METABOLISM AND ITS REGULATION</b> .....	216
Principles and Control of Lipid Metabolism (Tables 1, 2) .....	216
<b>KEY CONCEPTS: LIPID AND LIPOPROTEIN DISORDERS</b> .....	219
Cardiovascular Disease Risk Calculation and Evaluation .....	219
<i>Disorders Related to Lipid and Lipoprotein (Tables 3 - 6) [1 - 5]</i> .....	219
<b>KEY CONCEPTS: FATTY ACID TRANSPORT AND OXIDATION</b> .....	220
<b>KEY CONCEPTS: LIPID ABSORPTION, TRANSPORT, AND METABOLISM</b> .....	220
<b>KEY CONCEPTS: LIPOPROTEIN METABOLISM: ENDOGENOUS AND EXOGENOUS</b>	
<b>PATHWAYS</b> .....	221
Biochemical Basis, Relevant Lab Tests, Interpretation, and Applied Aspects .....	221
<i>Biochemical and Clinical Laboratory Methods for Detection, Diagnosis, and</i>	
<i>Management of Disorders Relating to Lipid and Lipoprotein Disorders (Tables 7-11)</i>	
<i>[1 - 5]</i> .....	221
Relevant Laboratory Tests, Analytics Methods Available, and Applied Aspects .....	223
<i>Specific Laboratory Investigations to Study the Disorders of Lipid and Lipoprotein</i>	
<i>Metabolism: Interpretation, Analytical Methods available (Tables 12-22; Fig. 1) [1 -</i>	
<i>5]</i> .....	223
<b>SUMMARY</b> .....	227
<b>EXERCISES</b> .....	227
<b>CONCLUSION</b> .....	227
<b>ACKNOWLEDGEMENT AND CONFLICT OF INTEREST</b> .....	227
<b>REFERENCES</b> .....	227
<b>CHAPTER 15 MINERALS: CALCIUM, MAGNESIUM, PARATHYROID, BONE</b>	
<b>DISORDERS</b> .....	229
<b>LEARNING OBJECTIVES</b> .....	229
<b>KEY CONCEPTS: CALCIUM AND PHOSPHATE HOMEOSTASIS</b> .....	230
Control of Calcium and Phosphate Homeostasis (Table 1) .....	230
Biochemical Basis, Relevant Lab Tests, Interpretation, and Applied Aspects .....	231
<i>Laboratory Investigations in Detection, Diagnosis, and Management of Disorders</i>	
<i>(Table 2)</i> .....	231
Relevant Laboratory Tests, Analytics Methods Available, and Applied Aspects .....	233
<i>Laboratory Investigations for Studying Calcium and Phosphate Metabolism and Bone</i>	
<i>Disease and Available Analytical Methods (Table 3) [1 - 5]</i> .....	233

<b>SUMMARY</b> .....	234
<b>EXERCISE</b> .....	234
<b>CONCLUSION</b> .....	235
<b>ACKNOWLEDGEMENT AND CONFLICT OF INTEREST</b> .....	235
<b>REFERENCES</b> .....	235
<b>CHAPTER 16 MUSCULOSKELETAL DISEASES</b> .....	236
<b>LEARNING OBJECTIVES</b> .....	236
<b>KEY CONCEPTS: APPLIED ASPECTS OF MUSCLE FUNCTION</b> .....	237
Muscle Function and the Use of Autoimmune Testing in Diagnosis (Table 1,2) [1 - 4] .....	237
<b>KEY CONCEPTS: USE AND LIMITATIONS OF AUTOIMMUNE TESTING IN</b>	
<b>DIAGNOSIS</b> .....	238
Disease .....	238
<i>Biochemical Basis, Relevant Lab Tests, Interpretation of Results</i> .....	238
Relevant Laboratory Tests, Analytics Methods Available, and Applied Aspects for .....	241
<i>Analytical Methods Available for Laboratory Investigations and Interpretation of</i>	
<i>Analytical Results (Tables 9 - 14) [1 - 4]</i> .....	241
<b>SUMMARY</b> .....	243
<b>CONCLUSION</b> .....	243
<b>EXERCISES</b> .....	244
<b>ACKNOWLEDGEMENT AND CONFLICT OF INTEREST</b> .....	244
<b>REFERENCES</b> .....	244
<b>CHAPTER 17 NEUROLOGICAL AND PSYCHIATRIC DISORDERS</b> .....	245
<b>LEARNING OBJECTIVES</b> .....	245
<b>KEY CONCEPTS</b> .....	246
Biochemical Basis and Clinical Manifestations of Neurological and Psychiatric Disorders	
(Tables 1 and 2) [1 - 3] .....	246
Biochemical Basis, Relevant Lab Tests, Interpretation, and Applied Aspects .....	247
<i>Biochemical Basis, Relevant Lab Tests, Interpretation, and Applied Aspects of</i>	
<i>Neurological and Psychiatric Disorders (Tables 3-8)</i> .....	247
Laboratory Investigations .....	250
<i>Laboratory Investigations in their Detection, Diagnosis, and Management and</i>	
<i>Interpretation (Tables 9 - 19) [4]</i> .....	250
<b>SUMMARY</b> .....	254
<b>EXERCISES</b> .....	254
<b>CONCLUSION</b> .....	254
<b>REFERENCES</b> .....	254
<b>CHAPTER 18 PEDIATRIC CLINICAL CHEMISTRY</b> .....	256
<b>LEARNING OBJECTIVES</b> .....	256
<b>KEY CONCEPTS</b> .....	257
Key Concepts in General Pediatric Clinical Laboratory Service .....	257
<i>Special Considerations in Relation to the Provision of a General Pediatric Clinical</i>	
<i>Laboratory Service (Table 1)</i> .....	257
<b>DISEASES</b> .....	258
Biochemical Basis, Relevant Lab Tests, Interpretation of Results, and Applied Aspects for	
<i>Laboratory Investigations in Detection, Diagnosis and Management of Disorders</i>	
<i>Presenting in the Neonate and in Childhood (Table 2) [1 - 4]</i> .....	258
<b>LABORATORY INVESTIGATIONS</b> .....	260
Relevant Laboratory Tests for Detection, Diagnosis, and Management, or Monitoring	
Analytics Methods Available and Applied Aspects for .....	260

<i>Laboratory Investigations, Analytical Methods and Interpretation of Analytical Results (Table 3) [1 - 4]</i> .....	260
<b>SUMMARY</b> .....	261
<b>EXERCISES</b> .....	262
<b>CONCLUSION</b> .....	262
<b>REFERENCES</b> .....	262
<b>CHAPTER 19 PREGNANCY AND PRENATAL DIAGNOSIS</b> .....	263
<b>LEARNING OBJECTIVES</b> .....	263
<b>KEY CONCEPTS</b> .....	264
Key Concepts and Applied Aspects of Laboratory Medicine Support Related to Maternal and Fetal Health During Pregnancy .....	264
<i>Laboratory Medicine Support Related to the Health of the Mother and Fetus During Pregnancy (Table 1)</i> .....	264
Laboratory Tests During Pregnancy .....	265
<i>Laboratory Investigations for Complications of Pregnancy and Fetal Development (Table 2 - 6)</i> .....	265
<b>DISEASE</b> .....	268
Biochemical Basis, Relevant Lab Tests, Interpretation, and Applied Aspects .....	268
<i>Laboratory Investigations for Complications of Pregnancy and Fetal Development, Interpretation and Applied Aspects (Tables 7-16) [1 - 5]</i> .....	268
<b>DISORDERS</b> .....	271
Biochemical Basis, Relevant Lab Tests, Interpretation, and Applied Aspects .....	271
<i>Biochemical Basis, Relevant Lab Tests, Interpretation, and Applied Aspects (Tables 17 - 27) [1 - 5]</i> .....	271
<b>LABORATORY INVESTIGATIONS</b> .....	275
Relevant Laboratory Tests for the Detection, Diagnosis, Management, or Monitoring During Pregnancy .....	275
<i>Laboratory Tests for the Detection, Diagnosis, Management, or Monitoring During Pregnancy (Table 28)</i> .....	275
<b>SUMMARY</b> .....	276
<b>EXERCISES</b> .....	276
<b>CONCLUSION</b> .....	276
<b>REFERENCES</b> .....	277
<b>CHAPTER 20 THERAPEUTIC DRUG MONITORING AND TOXICOLOGY</b> .....	278
<b>LEARNING OBJECTIVES</b> .....	278
<b>KEY CONCEPTS</b> .....	279
Key Concepts of Pharmacology: Mode of Action and Clinical Uses of a Drug, Drug Action, and Measurement .....	279
<i>Pharmacology and Key Factors Relevant to Drug Action and Measurement (Table 1)</i> .....	279
Biochemical Basis, Relevant Lab Tests, Interpretation of Results, and Applied Aspects for <i>Laboratory Investigations, Analytical Methods and Interpretation of Analytical Results (Table 2) [1-3]</i> .....	279
Laboratory Tests, Analytics Methods Available, and Applied Aspects of Therapeutic Drug Monitoring (TDM) .....	283
<i>Laboratory Investigations, Analytics Methods Available and Therapeutic Drug Monitoring and Toxicology (Table 3 - 5) [1 - 4]</i> .....	283
<b>SUMMARY</b> .....	285
<b>EXERCISES</b> .....	285
<b>CONCLUSION</b> .....	286
<b>REFERENCES</b> .....	286

<b>CHAPTER 21 VITAMINS AND TRACE ELEMENTS</b> .....	287
<b>LEARNING OBJECTIVES</b> .....	287
<b>KEY CONCEPTS</b> .....	288
Key Concepts and Applied Aspects of Trace Elements and Vitamins .....	288
<i>Trace Elements and Vitamins: Mechanisms of Actions and the Consequences of</i> <i>Deficiency and Overload States (Table 1) [1, 2]</i> .....	288
<b>DISEASE</b> .....	291
Biochemical Basis, Relevant Lab Tests, Interpretation of Results, and Applied Aspects .....	291
<i>Laboratory Investigations for Trace Elements and Vitamins, and Interpretation of the</i> <i>Analytical Results (Table 2) [1 - 3]</i> .....	291
<b>DISORDERS</b> .....	293
Interpretation of Analytical Results and Analytical Methods Available for the Laboratory Tests .....	293
<i>Laboratory Investigations for Trace Elements and Vitamins, Analytical Methods</i> <i>Available and Interpretation of the Analytical Results (Table 3) [1 - 3]</i> .....	293
<b>SUMMARY</b> .....	294
<b>EXERCISES</b> .....	295
<b>CONCLUSION</b> .....	295
<b>REFERENCES</b> .....	295
<b>SUBJECT INDEX</b> .....	296

## PREFACE

The book *Mind Maps in Clinical Chemistry for Core Competencies in Laboratory Diagnostics* is for students studying clinical biochemistry as part of their medical, nursing, or biomedical science courses and for those preparing for postgraduate entrance and board examinations. The book has unique learning modules designed on the outline of clinical chemistry and laboratory evaluation of disease with a focus on clinical cases. It will serve as a companion for the core competencies for the general clinical chemistry exam conducted by various Clinical Chemistry Boards.

The outline of this book has the headings of: *Key concepts; biochemical basis, relevant lab tests, interpretation and applied aspects; relevant laboratory tests for detection, diagnosis, management, and monitoring; relevant laboratory tests, analytics methods available and applied aspects.*

This book is a learning tool for imparting mastery and knowledge of clinical chemistry interpretation and problem-solving for preparing for exams and board certifications.

**Simmi Kharb**

Department of Biochemistry  
Pt. B.D. Sharma Post Graduate Institute of Medical Sciences (PGIMS)  
Rohtak 124001, Haryana, India

## CHAPTER 1

# Disorders of Acid-Base and Pulmonary Function

**Abstract:** The chapter discusses the critical clinical conditions related to acid-base balance and pulmonary function. It emphasizes the importance of identifying and managing acid-base disorders through ABG interpretation and serum electrolyte analysis. Additionally, it highlights the essential role of Pulmonary Function Tests (PFTs) in diagnosing and managing respiratory conditions such as COPD and asthma.

### LEARNING OBJECTIVES

After reading this chapter, the reader should be able to:

1. Describe the principles and control of acid-base balance and pulmonary function
2. Discuss the causes, clinical signs, and symptoms of the disorders relating to acid-base balance and pulmonary function
3. Describe the laboratory investigations that are important in their detection, diagnosis, and management
4. Describe the specific laboratory investigations important to the study of acid-base balance and pulmonary function
5. Understand the principle of their measurement
6. Selection, interpretation, and clinical correlation of laboratory investigations

### KEY CONCEPTS

Key Concepts: Acid-base Regulation and Pulmonary Function:

Principles and control of acid-base balance and pulmonary function

#### **Acid-base balance and pulmonary functions [1,2]**

##### *Acid-base balance*

Regulated tightly.

Arterial blood pH: 7.38-7.42, kept constant by buffer solutions.

### ***Acid-base homeostasis***

The body is highly sensitive to changes in its pH levels.

Body pH is maintained.

To maintain this, strong mechanisms are in place.

*If pH is outside the acceptable range, there is:*

Protein denaturation and digestion

Loss of the ability of an enzyme to function

Compromised ability of the body to maintain homeostasis, making survival incompatible with life

Chances of death.

### ***Buffer***

A mixture of a weak acid and its conjugate base, *or*

A mixture of a weak base and its conjugate acid

When a small amount of strong acid or base is added to it, very little change occurs in the pH.

*Extracellular buffers* include: bicarbonate, ammonia.

*Intracellular buffers* include: proteins, phosphates.

### ***Buffer systems and various organs maintain extracellular pH***

These systems maintain a pH value of 7.36-7.44.

The respiratory system modulates pCO<sub>2</sub>.

Kidneys modulate the concentration of bicarbonate.

### ***Buffers***

#### **Bicarbonate**

This helps regulate and maintain optimal pH levels.

This regulates the concentration of carbon dioxide.

**Le Chatelier's principle**

When a chemical system at equilibrium experiences a *change in concentration, temperature, or total pressure*, its equilibrium shifts to minimize the change.

In the context of acid-base imbalances:

Acid-base imbalances are *overcome* by short-term compensation *via*:

A change in the ventilation rate alters the blood carbon dioxide to alter pH.

***Renal compensation***

Slowest to compensate.

The kidney *controls pH by excreting excess acid or base*.

**Acidosis**

*Compensation by renal tubules:*

Bicarbonate is absorbed by renal tubular cells.

*Compensation by collecting duct:*

Hydrogen secretion.

Bicarbonate generation.

*Ammoniogenesis*: increase in  $\text{NH}_3$  buffer.

**Alkalosis**

Bicarbonate excretion.

*Compensation by renal tubules:*

Decreased hydrogen ion secretion.

Decreasing glutamine metabolism: ammonium excretion decreased.

***Regulation of pH by lungs***

*Via* changes in the rate of respiration to:

Expel  $\text{CO}_2$ .

**CHAPTER 2****Cancer**

**Abstract:** Cancer continues to stand as one of the foremost causes of morbidity and mortality worldwide, placing a substantial burden on healthcare systems. The evolution of clinical chemistry has facilitated the identification and utilization of diverse biomarkers that play pivotal roles in the early detection, diagnosis, monitoring, and therapeutic management of cancer. This module delves into the biochemical fundamentals of cancer, the significance of cancer biomarkers, the implementation of molecular diagnostic techniques, and the criticality of therapeutic monitoring. A deeper comprehension of these facets is imperative for clinical chemists to make meaningful contributions to the multidisciplinary team in the battle against cancer.

**Keywords:** Malignancy, paraneoplastic syndrome, ectopic hormone, multiple endocrine neoplasia, endocrine syndromes, carcinoid tumor, APUD tumors.

**LEARNING OBJECTIVES**

After reading this chapter, the reader should be able to understand and interpret:

- Biochemical aspects of monitoring malignant disease
- Key concepts relating to the choice, use, and measurement of biomarkers of malignancy
- Ideal tumor/cancer biomarkers
- Uses and limitations of current biomarkers of cancer
- Uses of biomarkers of cancer: prognosis, monitoring, and recurrence
- Specific laboratory investigations in the management of malignant diseases
- Analytical methods available for their measurement
- Interpret the analytical results in the context of the clinical signs and symptoms

**KEY CONCEPTS****Biochemical Aspects of Monitoring Malignant Disease [1 - 5]**

Monitoring of malignant diseases involves the evaluation of different biochemical factors for assessing the progression of the disease, the response to treatment, and the overall prognosis for the patient (Table 1-3).

**Table 1. Biochemical changes in cancer [3, 4].**

<p style="text-align: center;"><u><i>Biochemical changes in cancer:</i></u></p> <p>The biochemical effects of cancer can be <i>direct and indirect</i>:</p> <p style="text-align: center;"><i>i. Direct effects:</i> caused by:</p> <p style="text-align: center;">Infiltration into normal tissue by the tumor Expansion of primary and secondary tumors</p> <p style="text-align: center;"><i>Result:</i></p> <p style="text-align: center;">Obstruction of venous, lymphatic, or arterial supply→ Edema, infarction, retention of secretions or excretions→ Secondary infection or inflammatory response. Obstruction of the draining ducts of organs (<i>e.g.</i>, the Bile duct in the liver and the ureters from the kidneys) has profound metabolic consequences.</p> <p style="text-align: center;"><i>ii. Indirect effects:</i></p> <p>Effects not related to direct tumor invasion of normal tissue occur due to the production of <i>hormones, peptides, or other biologically active factors</i> that act at a site remote from the tumor.</p> <p>Metabolic changes in cancer are not always due to aberrant hormone secretion but may be due to some other effect of the tumor or as a consequence of treatment.</p> <p style="text-align: center;"><i>Blood picture:</i></p> <p style="text-align: center;">i. High serum calcium, uric acid, lactate, globulin, potassium, and phosphate. ii. Low serum fasting glucose, albumin, and magnesium.</p> <p style="text-align: center;"><i>iii. Anemia:</i></p> <p style="text-align: center;"><i>Cause:</i> Hemorrhage, hemolysis, malnutrition, or bone marrow infiltration by tumor cells.</p> <p style="text-align: center;">iv. <i>Hypercoagulable state</i> resulting in thromboembolism</p> <p style="text-align: center;"><b>2. Cancer cachexia:</b></p> <p style="text-align: center;">A syndrome of weakness and generalized wasting.</p> <p><i>Causes:</i> deficient food intake, intestinal obstruction or anorexia of malignancy, malabsorption, increased demands and consumption of nutrients by tumor, and the release of cachectin (TNF<math>\alpha</math>).</p>
--

**Table 2. Tumor products as markers of malignancy.**

<p style="text-align: center;"><u><i>Tumor products as markers of malignancy:</i></u></p> <p>Tumor products, also known as <i>tumor markers or biomarkers</i>, are substances produced by cancer cells or the body's response to cancer that can be detected in blood, urine, or tissue samples.</p> <p>These markers can serve as <i>indicators of malignancy</i> and provide valuable information for <i>cancer diagnosis, prognosis, treatment selection, monitoring, and recurrence detection</i>.</p> <p style="text-align: center;"><i>Common tumor products used as markers of malignancy include:</i></p> <p style="text-align: center;"><i>Carcinoembryonic Antigen (CEA)</i> <i>Prostate-specific Antigen (PSA)</i> <i>CA 125</i> <i>CA 19-9</i> <i>Alpha-Fetoprotein (AFP)</i> <i>Human Chorionic Gonadotropin (hCG):</i> <i>Thyroglobulin</i> <i>HER2/neu</i> <i>Melanoma-specific Markers (e.g., S100, Melan-A)</i></p> <p>These tumor products play a crucial role in <i>cancer diagnosis, prognosis, and management</i>, providing valuable information to clinicians for making informed treatment decisions and optimizing patient care.</p> <p>However, elevated levels of these markers are not specific to cancer and can also occur in non-cancerous conditions, so their interpretation should be done in conjunction with other diagnostic tests and clinical evaluation.</p>
--

Table 3. Biochemical consequences of neoplasia on other systems.

<p><u>Biochemical consequences of neoplasia on other systems:</u></p> <p>Include:</p> <p><b>1. Immune System Dysregulation:</b></p> <p>Tumors may produce factors that suppress immune responses:          Allowing the tumor to evade detection and destruction by immune cells          Tumors may stimulate inflammatory responses, leading to the production of cytokines and other immune mediators that can promote tumor growth and metastasis.</p> <p><b>2. Hormonal Imbalance:</b></p> <p>Certain tumors of the endocrine system secrete hormones or hormone-like substances that can disrupt normal hormonal balance</p> <p><i>Example:</i>          Tumors of the adrenal glands may produce excessive levels of cortisol, leading to Cushing's syndrome          Tumors of the pituitary gland may secrete growth hormone, causing acromegaly.</p> <p><b>3. Metabolic Disturbances:</b></p> <p>Tumors can alter metabolism by:          Increasing energy consumption and nutrient utilization to support their growth and proliferation          This may result in systemic metabolic disturbances:          Cachexia (muscle wasting), hyperglycemia, and dyslipidemia</p> <p><b>4. Electrolyte Imbalance:</b></p> <p>Some tumors of the endocrine system may produce hormones or hormone-like substances that affect electrolyte balance.</p> <p><i>Examples:</i>          Tumors of the parathyroid gland may secrete parathyroid hormone, leading to hypercalcemia.</p> <p><b>5. Hematological Effects:</b></p> <p>Tumors can cause abnormalities in blood cell production and function, leading to anemia, leukopenia, and thrombocytopenia.          Tumors may infiltrate bone marrow, impairing blood cell production.</p> <p><b>6. Organ Dysfunction:</b></p> <p>Tumors located near or within vital organs can directly impair organ function by compressing tissues, obstructing blood flow, or causing structural damage.          For example, tumors in the brain may increase intracranial pressure, leading to neurological symptoms and deficits.</p> <p><b>7. Systemic Inflammation:</b></p> <p>Chronic inflammation, being a hallmark of cancer, can contribute to tumor progression and metastasis.          Tumors produce inflammatory cytokines and chemokines that stimulate immune cell infiltration and promote angiogenesis.</p> <p><b>8. Oxidative Stress:</b></p> <p>Reactive Oxygen Species (ROS) are produced by tumors, leading to oxidative stress and cellular damage.          Neoplasia causes widespread biochemical effects on the body, affects multiple systems, and contributes to the systemic manifestations of cancer.</p> <p>Understanding of these biochemical consequences is essential for developing targeted therapies and interventions for managing cancer-related complications and improve patient outcomes.</p>
--

**CHAPTER 3****Cardiovascular Disorders and Hypertension Diseases**

**Abstract:** Cardiovascular disorders like coronary artery disease, myocardial infarction, heart failure, and hypertension are major causes of illness and death globally. Laboratory testing is crucial for diagnosis and management. Key biomarkers such as troponins, BNP, lipids, and electrolytes play a vital role in clinical decision-making. Hypertension, a major risk factor for cardiovascular disease, requires careful monitoring through blood pressure measurements and specific laboratory tests. This module covers the biochemical basis of these diseases, laboratory diagnostics, and clinical approaches to patient management.

**LEARNING OBJECTIVES**

1. Describe the causes and manifestations of cardiovascular disease and the assessment of individual risk for cardiovascular disorders.
2. Describe the laboratory investigations that are important in the detection, diagnosis, and management.
3. Select and interpret the results of the laboratory tests and recognize the analytical methods available.

**KEY CONCEPTS**

CAUSES AND MANIFESTATIONS OF CARDIOVASCULAR DISEASE AND THE ASSESSMENT OF INDIVIDUAL RISK FOR CARDIOVASCULAR DISORDERS.

**Acute Coronary Syndrome*****Acute Coronary Syndrome (ACS) [1]***

*Def.:* It refers to a range of conditions associated with sudden, reduced blood flow to the heart. It includes conditions such as unstable angina, non-ST-segment Elevation Myocardial Infarction (NSTEMI), and ST-segment Elevation Myocardial Infarction (STEMI).

Simmi Kharb

All rights reserved-© 2026 Bentham Science Publishers

**Biochemical Basis**

Involves complex interactions between lipids, inflammatory processes, and hemodynamic factors (Table 1).

**Table 1. Biochemical basis of causes and clinical signs and symptoms of ACS.**

<i>Aspect (cause)</i>	<i>Biochemical Basis</i>	<i>Causes</i>	<i>Clinical Signs and Symptoms</i>	<i>Biochemical Basis of Symptoms</i>
Atherosclerosis	Elevated LDL, Decreased HDL, Increased triglycerides	Chronic buildup of plaque in the coronary arteries	-	-
Plaque Rupture/Erosion	<i>Inflammatory mediators:</i> <i>e.g.,</i> CRP interleukins <i>Proteolytic enzymes:</i> <i>e.g.,</i> MMPs	Disruption of atherosclerotic plaque	-	-
Thrombus Formation	<i>Platelet activation:</i> Thromboxane A2 ADP Fibrinogen Coagulation cascade: Thrombin Fibrin	Formation of a blood clot obstructing blood flow in the coronary artery	-	-
Coronary Artery Spasm	<i>Imbalances in endothelial function:</i> Increased endothelin-1, Decreased NO	Sudden, temporary narrowing of a coronary artery	-	-
Chest Pain (Angina Pectoris)	Ischemia-induced release of adenosine and lactic acid	-	Sudden, severe, crushing chest pain, radiating to the neck, jaw, shoulder, or arm	Release of pain-inducing substances due to ischemia
Shortness of Breath (Dyspnea)	Myocardial ischemia and center ventricular dysfunction	-	Difficulty breathing	Pulmonary congestion and reduced oxygen delivery
Diaphoresis (Sweating)	Activation of the sympathetic nervous system	-	Excessive sweating	Increased sweat gland activity due to stress and pain
Nausea and Vomiting	Vagal nerve stimulation	-	Feeling of sickness with or without vomiting	Vagal response to myocardial ischemia and pain

*(Table 1) cont....*

<i>Aspect (cause)</i>	<i>Biochemical Basis</i>	<i>Causes</i>	<i>Clinical Signs and Symptoms</i>	<i>Biochemical Basis of Symptoms</i>
Palpitations	Arrhythmias due to altered ion channel function and disrupted electrical conduction	-	Rapid, strong, or irregular heartbeat	Ischemia-induced electrical disturbances
Fatigue and Weakness	Reduced cardiac output and poor tissue perfusion	-	Unexplained tiredness or weakness	Decreased oxygen and nutrient delivery to tissues
Syncope (Fainting)	Severe reduction in cardiac output leading to decreased cerebral perfusion	-	Temporary loss of consciousness	Insufficient blood flow to the brain

### ***Causes of ACS***

1. Atherosclerosis
2. Plaque Rupture or Erosion
3. Thrombus Formation
4. Coronary Artery Spasm

### ***Clinical Signs and Symptoms of Acute Coronary Syndrome***

1. Chest Pain (Angina Pectoris): Sudden, severe, and crushing chest pain radiating to the neck, jaw, shoulder, or arm.
2. Shortness of Breath (Dyspnea): Difficulty breathing, which may accompany or follow chest pain.
3. Diaphoresis (Sweating): Excessive sweating.
4. Nausea and Vomiting: Feeling of sickness with or without vomiting.
5. Palpitations: Feeling of rapid, strong, or irregular heartbeat.
6. Fatigue and Weakness: Unexplained tiredness or weakness.
7. Syncope (Fainting): Temporary loss of consciousness.

### **KEY CONCEPTS: BIOCHEMICAL BASIS OF CAUSES AND CLINICAL SIGNS AND SYMPTOMS OF ACS**

#### **Key Concepts: Biochemical Changes of Disease or Disorder**

The biochemical changes in ACS are a complex interplay of myocardial injury, inflammation, lipid metabolism, coagulation, oxidative stress, and endothelial dysfunction (Table 2).

## Diabetes Mellitus

**Abstract:** Diabetes Mellitus (DM) is a chronic disorder characterized by high blood sugar levels due to issues with insulin secretion or action. Type 1 DM is autoimmune, while Type 2 DM is linked to insulin resistance and obesity. Diagnosis and monitoring involve tests. Advanced tests, such as C-peptide, help differentiate between Type 1 and Type 2 diabetes. Early detection and tight control of blood glucose levels are vital in preventing complications such as diabetic ketoacidosis, retinopathy, nephropathy, and cardiovascular diseases.

### LEARNING OBJECTIVES

After going through this chapter, one should be able to:

- Describe the pathogenesis of diabetic states and the applied aspects of the study of diabetes mellitus.
- Describe the causes, clinical signs, and symptoms of applied aspects of diabetes mellitus.
- Describe the laboratory investigations that are important in the detection, diagnosis, and management of complications.
- Describe the specific laboratory investigations important to the study of diabetes mellitus.
- Recognize analytical methods available for their measurement.
- Select laboratory investigations and interpret the analytical results in the context of clinical signs and symptoms.

### KEY CONCEPTS: PATHOGENESIS OF DIABETIC STATES AND REGULATION OF GLUCOSE HOMEOSTASIS

#### Pathogenesis of Diabetic States and the Applied Aspects of the Study of Diabetes Mellitus (Table 1) [1]

Table 1. Pathogenesis of diabetic states.

Aspect	Type 1 Diabetes Mellitus (T1DM)	Type 2 Diabetes Mellitus (T2DM)
<b>Pathogenesis</b>	- Autoimmune destruction of $\beta$ -cells	- Insulin resistance in peripheral tissues (muscle, fat, liver)
	- Genetic susceptibility ( <i>e.g.</i> , HLA-DR3, HLA-DR4)	- $\beta$ -cell dysfunction over time
	- Environmental triggers ( <i>e.g.</i> , viral infections, dietary factors, toxins)	- Strong association with obesity, sedentary lifestyle, and genetic predisposition
<b>Insulin</b>	- Secreted by pancreatic $\beta$ -cells	- Secreted by pancreatic $\beta$ -cells
<b>Primary Function</b>	- Lowers blood glucose levels	- Lowers blood glucose levels
<b>Mechanisms</b>	- Promotes glucose uptake in muscle and adipose tissue	- Promotes glucose uptake in muscle and adipose tissue
	- Stimulates glycogenesis (conversion of glucose to glycogen)	- Stimulates glycogenesis (conversion of glucose to glycogen)
	- Encourages lipogenesis (fatty acid synthesis) and inhibits lipolysis	- Encourages lipogenesis (fatty acid synthesis) and inhibits lipolysis
	- Enhances protein synthesis and inhibits protein degradation	- Enhances protein synthesis and inhibits protein degradation
<b>Glucagon</b>	- Secreted by pancreatic $\alpha$ -cells	- Secreted by pancreatic $\alpha$ -cells
<b>Primary Function</b>	- Raises blood glucose levels	- Raises blood glucose levels
<b>Mechanisms</b>	- Stimulates glycogenolysis (breakdown of glycogen to glucose)	- Stimulates glycogenolysis (breakdown of glycogen to glucose)
	- Promotes gluconeogenesis (synthesis of glucose from non-carbohydrate substrates)	- Promotes gluconeogenesis (synthesis of glucose from non-carbohydrate substrates)
<b>Other Hormones Involved</b>	- Epinephrine: Increases blood glucose by promoting glycogenolysis and gluconeogenesis	- Epinephrine: Increases blood glucose by promoting glycogenolysis and gluconeogenesis
	- Cortisol: Enhances gluconeogenesis and inhibits glucose uptake in tissues	- Cortisol: Enhances gluconeogenesis and inhibits glucose uptake in tissues
	- Growth Hormone: Reduces glucose uptake in tissues and increases lipolysis	- Growth Hormone: Reduces glucose uptake in tissues and increases lipolysis
<b>Regulatory Pathways</b>	- Fed State: High blood glucose levels stimulate insulin release	- Fed State: High blood glucose levels stimulate insulin release
	- Fasting State: Low blood glucose levels stimulate glucagon release	- Fasting State: Low blood glucose levels stimulate glucagon release
<b>Dysregulation in Diabetes</b>	- Lack of insulin leads to unopposed glucagon action	- Insulin resistance and $\beta$ -cell dysfunction result in impaired glucose uptake

*(Table 1) cont....*

Aspect	Type 1 Diabetes Mellitus (T1DM)	Type 2 Diabetes Mellitus (T2DM)
	- Causes hyperglycemia, ketogenesis, and metabolic acidosis	- Causes increased hepatic glucose production and chronic hyperglycemia
<b>Clinical Implications</b>	- Diagnosis: Based on fasting glucose levels, HbA1c, and glucose tolerance tests	- Diagnosis: Based on fasting glucose levels, HbA1c, and glucose tolerance tests
	- Management: Insulin therapy is essential	- Management: Lifestyle modification, oral hypoglycemic agents, insulin therapy
	- Complications: Leads to microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (cardiovascular disease) complications	- Complications: Leads to microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (cardiovascular disease) complications

## KEY CONCEPTS: DYSREGULATION OF GLUCOSE HOMEOSTASIS IN DIABETES MELLITUS

### Causes, Clinical Signs and Symptoms of Applied Aspects of Diabetes Mellitus (Table 2). [1 - 3]

Table 2. Key aspects of diabetes.

Aspect	Type 1 Diabetes Mellitus (T1DM)	Type 2 Diabetes Mellitus (T2DM)
<b>Pathogenesis</b>	- Autoimmune destruction of pancreatic $\beta$ -cells	- Insulin resistance in peripheral tissues (muscle, fat, liver)
	- Absolute insulin deficiency	- Progressive $\beta$ -cell dysfunction
<b>Insulin Levels</b>	- Severely reduced or absent	- Initially normal or elevated; decreases over time
<b>Glucagon Levels</b>	- Elevated due to lack of insulin inhibition	- Often elevated or inadequately suppressed
<b>Blood Glucose Regulation</b>	- Hyperglycemia due to lack of insulin-mediated glucose uptake	- Hyperglycemia due to insulin resistance and impaired insulin secretion
<b>Glycogen Metabolism</b>	- Decreased glycogen synthesis in the liver and muscle	- Impaired glycogen synthesis and increased glycogen breakdown
<b>Gluconeogenesis</b>	- Increased hepatic gluconeogenesis due to unopposed glucagon action	- Increased hepatic gluconeogenesis despite hyperinsulinemia
<b>Lipid Metabolism</b>	- Increased lipolysis leading to elevated free fatty acids	- Increased lipolysis and decreased lipid storage due to insulin resistance
	- Ketogenesis leading to ketoacidosis	- Mild ketogenesis, but usually not severe due to residual insulin activity
<b>Protein Metabolism</b>	- Increased proteolysis due to lack of insulin	- Increased proteolysis and reduced protein synthesis due to insulin resistance

## Disorders of the Kidney and Urinary Tract

**Abstract:** This chapter offers a comprehensive overview of disorders that affect the kidney and urinary tract. It explores their pathophysiology, clinical manifestations, diagnostic approaches, and treatment options. The chapter emphasizes both acute and chronic conditions, covering common issues such as infections, kidney stones, glomerulonephritis, and chronic kidney disease. It highlights the importance of early detection and intervention to prevent complications and improve patient outcomes. The chapter also discusses advances in diagnostic techniques and therapeutic strategies, as well as preventive measures and patient education. The information aims to equip professionals with the knowledge needed to effectively manage these disorders and improve patient care.

**Keywords:** Diagnostics, Kidney diseases, Kidney stones, Kidney, Techniques, Urinary tract.

### Learning objectives

By the end of this chapter, one should:

1. Be able to describe the principles and control of renal function and the urinary tract, and clinical interventions that supplement/replace declining renal function.
2. Be able to describe the causes, clinical signs, and symptoms of the following features of disorders relating to renal function, the urinary tract, and uric acid metabolism.
3. Be able to describe which laboratory investigations are important in their detection, diagnosis, and management.
4. Be able to recognize the analytical methods available for their measurement.
5. Be able to select laboratory investigations and interpret the analytical results in the context of clinical signs and symptoms.

**KEY CONCEPTS****KEY CONCEPTS: Normal Renal Function*****Principles and Control of Renal Function (Table 1-3) [1-4]*****Table 1. Renal function.**

<b><i>Key Concept</i></b>	<b><i>Details</i></b>
<b><i>Filtration</i></b>	Glomerular Filtration: Blood is filtered in the glomeruli.
	GFR: Normal rate is 90-120 mL/min.
	Filtrate Composition: Includes water, electrolytes, glucose, amino acids, and waste products.
<b><i>Reabsorption</i></b>	Proximal Tubule: Reabsorbs the majority of water, electrolytes, glucose, and amino acids.
	Loop of Henle: Descending limb reabsorbs water; ascending limb reabsorbs sodium and chloride.

Renal function: details.

**Table 2. Details of renal function.**

<b><i>Key Concept</i></b>	<b><i>Details</i></b>
<b><i>Secretion</i></b>	Tubular Secretion: Active transport of substances from blood into tubular fluid.
	Substances Secreted: Hydrogen ions, potassium, ammonia, certain drugs, and toxins.
	Sites: Primarily in the proximal tubule, distal tubule, and collecting duct.
<b><i>Excretion</i></b>	Formation of Urine: Final adjustments in the collecting duct; urine flows to the bladder for storage and excretion.
	Urine Composition: Water, urea, creatinine, uric acid, electrolytes, and other metabolic waste products.
<b><i>Regulation of Blood Pressure</i></b>	RAAS: Renin released in response to low BP; angiotensin II increases BP; aldosterone increases Na <sup>+</sup> reabsorption.
<b><i>Electrolyte Balance</i></b>	Sodium (Na <sup>+</sup> ): Regulated by aldosterone.
	Potassium (K <sup>+</sup> ): Regulated by aldosterone.
	Calcium (Ca <sup>2+</sup> ): Reabsorption influenced by PTH.
	Phosphate (PO <sub>4</sub> <sup>3-</sup> ): Excretion influenced by PTH.
<b><i>Acid-Base Balance</i></b>	Bicarbonate Reabsorption: Occurs in the proximal tubule.
	Hydrogen Ion Secretion: Occurs in the proximal tubule, distal tubule, and collecting duct.
<b><i>Erythropoiesis</i></b>	Erythropoietin (EPO) Production: Stimulated by low oxygen levels; promotes red blood cell production.

*(Table 2) cont....*

<b>Key Concept</b>	<b>Details</b>
<b>Waste Removal</b>	Urea: Byproduct of protein metabolism.
	Creatinine: Byproduct of muscle metabolism.
	Uric Acid: Byproduct of purine metabolism.
<b>Water Balance</b>	Antidiuretic Hormone (ADH): Increases water reabsorption in the collecting ducts; concentrates urine.

Key concepts: Endocrine functions of the kidney.

**Table 3. Renal function: endocrine functions.**

<b>Endocrine Function</b>	<b>Details</b>
<b>Erythropoietin (EPO) Production</b>	Stimulus: Low oxygen levels in the blood.
	Role: Stimulates red blood cell production in the bone marrow.
	Effect: Increases oxygen-carrying capacity of the blood.
<b>Renin-Angiotensin-Aldosterone System (RAAS)</b>	Renin Release: Produced by juxtaglomerular cells in response to low blood pressure or sodium levels.
	Angiotensin II: Formed from angiotensin I, a potent vasoconstrictor, raises blood pressure.
	Aldosterone: Stimulated by angiotensin II, increases sodium and water reabsorption, raises blood pressure.
<b>Vitamin D Activation</b>	Conversion: Converts inactive vitamin D (calcidiol) to the active form (calcitriol).
	Role of Calcitriol: Enhances calcium and phosphate absorption from the gut.
	Effect: Regulates calcium and phosphate homeostasis, essential for bone health.
<b>Prostaglandin Production</b>	Function: Produces prostaglandins, which regulate blood flow within the kidneys.
	Effects: Modulate inflammation, influence kidney function, and affect blood pressure regulation.
<b>Regulation of Blood Pressure</b>	Mechanisms: Through RAAS and the production of prostaglandins.
	Effects: Maintains systemic blood pressure and renal perfusion.
<b>Glucose Homeostasis</b>	Gluconeogenesis: Kidneys produce glucose from non-carbohydrate sources during fasting states.
	Hormonal Influence: Insulin and other hormones regulate this process.

**CHAPTER 6****Endocrinology**

**Abstract:** Endocrinology, a critical branch of medicine, deals with the endocrine system, its diseases, and the secretions known as hormones. It plays a vital role in maintaining homeostasis. This chapter delves into the practical aspects of endocrinology, specifically focusing on prevalent disorders such as diabetes mellitus, thyroid diseases, adrenal insufficiency, and growth disorders. The emphasis is placed on the biochemical pathways, diagnostic approaches, and therapeutic strategies. Significant advances in molecular diagnostics and personalized medicine have greatly enhanced the understanding and treatment of endocrine disorders, ultimately leading to improved patient outcomes.

**Keywords:** Adrenal insufficiency, Diseases, Diabetes mellitus, Endocrinology, Growth disorders, Lab diagnosis, Thyroid diseases.

**LEARNING OBJECTIVES**

By the end of this chapter, one should be able to:

- Understand and describe all aspects of hormone action and regulation.
- Understand the causes, clinical presentation, and laboratory diagnosis of endocrine disorders.
- Understand the relevance of laboratory investigations in the detection, diagnosis, and management of each endocrine disorder.
- Recognize the analytical methods available for their measurement.
- Select appropriate laboratory investigations and interpret the analytical results in the context of the clinical signs and symptoms in the patient.

**KEY CONCEPTS: HORMONE ACTION****Hormone Action and Regulation (Table 1,2) [1 - 3]**

Table 1. Hormone action and regulation.

<i>Key Concept</i>	<i>Feedback Inhibition</i>	<i>Other Regulatory Mechanisms</i>
<b>Hypothalamic-Pituitary Axis</b>	Hormone levels inhibit hypothalamic/pituitary release	Hypothalamic hormones, circadian rhythms, and neural inputs
<b>Anterior Pituitary Hormones</b>	Target gland hormones provide negative feedback	Releasing hormones ( <i>e.g.</i> , TRH, CRH, GnRH) and inhibitory hormones ( <i>e.g.</i> , somatostatin, dopamine)
<b>Pituitary-Hypothalamus Communication</b>	Feedback from target hormones	Anterior: <i>via</i> the hypophyseal portal system; Posterior: neural control
<b>Hirsutism and Virilization</b>	Androgens regulate LH/FSH levels	Abnormal feedback loops and direct gland dysfunction
<b>Hypothalamic Hormones</b>	Target gland hormones inhibit hypothalamic hormones	Neural inputs, stress, and circadian rhythms
<b>Inhibitory Hormones</b>	Target gland hormones inhibit hypothalamic/pituitary hormones	Somatostatin and dopamine inhibit GH and prolactin
<b>Posterior Pituitary Hormones</b>	Feedback from osmoreceptors, uterine stretch receptors	Neural signals from the hypothalamus control the release
<b>Primary vs. Secondary Causes</b>	Different patterns of hormone levels in primary vs. secondary disorders	Target gland hormone levels affect upstream regulation differently
<b>Renin-Angiotensin-Aldosterone Pathway</b>	Elevated BP/sodium inhibits renin release, reducing aldosterone	Blood pressure, sodium, and potassium levels regulate renin; aldosterone adjusts sodium/water reabsorption
<b>Steroid Biosynthesis Pathway</b>	Cortisol provides negative feedback to inhibit ACTH and CRH	Enzymatic control within the adrenal cortex and feedback from end products
<b>Stimulation Tests</b>	Assess gland responsiveness to feedback dysregulation	Administer stimulating agents ( <i>e.g.</i> , ACTH, TRH) to test functionality
<b>Suppression Tests</b>	Evaluate the ability of feedback to suppress hormone release	Administer suppressive agents ( <i>e.g.</i> , dexamethasone) to test negative feedback mechanisms

**KEY CONCEPTS: HYPOTHALAMIC- PITUITARY AXIS**

Table 2. Key concepts of hormone action and regulation.

<b>Key Concept</b>	<b>Feedback Inhibition</b>	<b>Other Regulatory Mechanisms</b>
<b>Hypothalamic-Pituitary Axis</b>	Hormone levels inhibit hypothalamic/pituitary release	Hypothalamic hormones, circadian rhythms, and neural inputs
<b>Anterior Pituitary Hormones</b>	Target gland hormones provide negative feedback	Releasing hormones ( <i>e.g.</i> , TRH, CRH, GnRH), inhibitory hormones ( <i>e.g.</i> , somatostatin, dopamine)
<b>Communication Between Pituitary and Hypothalamus – Anterior vs. Posterior</b>	Feedback from target hormones	Anterior: <i>via</i> the hypophyseal portal system; Posterior: neural control
<b>Hirsutism and Virilization</b>	Androgens regulate LH/FSH levels	Abnormal feedback loops, direct gland dysfunction
<b>Hypothalamic Hormones</b>	Target gland hormones inhibit hypothalamic hormones	Neural inputs, stress, and circadian rhythms
<b>Inhibitory Hormones</b>	Target gland hormones inhibit hypothalamic/pituitary hormones	Somatostatin and dopamine inhibit GH and prolactin
<b>Posterior Pituitary Hormones</b>	Feedback from osmoreceptors and uterine stretch receptors	Neural signals from the hypothalamus control the release
<b>Primary vs. Secondary Causes</b>	Different patterns of hormone levels in primary vs. secondary disorders	Target gland hormone levels affect upstream regulation differently
<b>Renin-Angiotensin-Aldosterone Pathway</b>	Elevated BP/sodium inhibits renin release, reducing aldosterone	Blood pressure, sodium, and potassium levels regulate renin; aldosterone adjusts sodium/water reabsorption
<b>Steroid Biosynthesis Pathway</b>	Cortisol provides negative feedback to inhibit ACTH and CRH	Enzymatic control within the adrenal cortex, feedback from end products
<b>Stimulation Tests</b>	Assess gland responsiveness to feedback dysregulation	Administer stimulating agents ( <i>e.g.</i> , ACTH, TRH) to test functionality
<b>Suppression Tests</b>	Evaluate the ability of feedback to suppress hormone release	Administer suppressive agents ( <i>e.g.</i> , dexamethasone) to test negative feedback mechanisms

## Fluid and Electrolyte Disorders

**Abstract:** Understanding and managing fluid and electrolyte disorders is crucial in clinical practice. This chapter explores the pathophysiology, diagnostic approaches, and management strategies for common disorders such as hyponatremia, hyperkalemia, and dehydration. Integration of biochemical data with clinical presentations is emphasized for comprehensive care planning.

**Keywords:** Fluid, Electrolyte, Hyponatremia, Hyperkalaemia, Dehydration.

- Understand the physiological mechanisms regulating fluid and electrolyte balance.
- Identify the causes and consequences of fluid and electrolyte disorders.
- Describe the laboratory tests used to diagnose fluid and electrolyte imbalances.
- Develop treatment strategies for managing fluid and electrolyte disorders.
- Apply clinical knowledge to interpret laboratory results in the context of patient symptoms.
- Evaluate the impact of fluid and electrolyte disorders on overall health and disease outcomes.

### KEY CONCEPTS

#### Basic Concept and Homeostasis Of Fluid And Electrolyte Balance

*Physiological Mechanisms Regulating Fluid And Electrolyte Balance  
(Table 1) [1-3]*

Table 1. Physiological mechanisms regulating fluid and electrolyte balance.

Key Concept	Description	Mechanisms and Regulation
<b>Total Body Water</b>	Comprises about 60% of body weight, divided into Intracellular Fluid (ICF) and Extracellular Fluid (ECF).	Regulated by intake and loss of fluids <i>via</i> the kidneys, skin, lungs, and GI tract.
<b>Intracellular Fluid (ICF)</b>	Fluid within cells, makes up about 40% of body weight.	Maintained by cell membrane permeability and osmotic gradients.
<b>Extracellular Fluid (ECF)</b>	Fluid outside cells, includes interstitial fluid, plasma, and transcellular fluid, makes up about 20% of body weight.	Regulated by capillary filtration and reabsorption, lymphatic drainage.
<b>Osmolality</b>	Measure of solute concentration in body fluids, normally around 275-295 mOsm/kg.	Controlled by ADH, the thirst mechanism, and renal function.
<b>Sodium (Na<sup>+</sup>)</b>	Major cation in ECF, crucial for maintaining fluid balance, nerve function, and muscle contraction.	Regulated by aldosterone, natriuretic peptides, and ADH.
<b>Potassium (K<sup>+</sup>)</b>	A major cation in ICF, essential for cell function, nerve impulses, and muscle contraction.	Regulated by aldosterone, insulin, and renal excretion.
<b>Calcium (Ca<sup>2+</sup>)</b>	Important for bone health, muscle contraction, nerve function, and blood clotting.	Controlled by Parathyroid Hormone (PTH), calcitonin, and vitamin D.
<b>Magnesium (Mg<sup>2+</sup>)</b>	Vital for enzyme activity, muscle and nerve function, and energy production.	Regulated by renal excretion and reabsorption, PTH.
<b>Chloride (Cl<sup>-</sup>)</b>	A major anion in ECF, helps maintain osmotic pressure and acid-base balance.	Regulated in conjunction with sodium by aldosterone.
<b>Bicarbonate (HCO<sub>3</sub><sup>-</sup>)</b>	A key component of the buffer system, helps maintain acid-base balance.	Regulated by the kidneys <i>via</i> reabsorption and secretion.
<b>Phosphate (PO<sub>4</sub><sup>3-</sup>)</b>	Important for energy production, bone health, and acid-base balance.	Regulated by PTH, vitamin D, and renal excretion.
<b>Acid-Base Balance</b>	Maintenance of pH within a narrow range (7.35-7.45), critical for normal cellular function.	Buffers (bicarbonate, phosphate, proteins), respiratory control of CO <sub>2</sub> , renal regulation of H <sup>+</sup> and HCO <sub>3</sub> <sup>-</sup> .
<b>Renal Regulation</b>	Kidneys play a crucial role in maintaining fluid and electrolyte balance by filtering blood, reabsorbing needed substances, and excreting waste and excess electrolytes.	Aldosterone increases Na <sup>+</sup> reabsorption and K <sup>+</sup> excretion; ADH increases water reabsorption; natriuretic peptides promote Na <sup>+</sup> and water excretion.
<b>Hormonal Control</b>	Hormones like ADH, aldosterone, and PTH regulate fluid and electrolyte balance.	ADH increases water reabsorption; aldosterone increases Na <sup>+</sup> reabsorption and K <sup>+</sup> excretion; PTH increases Ca <sup>2+</sup> reabsorption and PO <sub>4</sub> <sup>3-</sup> excretion.
<b>Thirst Mechanism</b>	Regulated by the hypothalamus, stimulates fluid intake in response to increased osmolality or decreased blood volume.	Activated by osmoreceptors in the hypothalamus and baroreceptors in the cardiovascular system.

(Table 1) cont....

Key Concept	Description	Mechanisms and Regulation
<b>Electrolyte Imbalances</b>	Can lead to clinical conditions like hyponatremia, hyponatremia, hyperkalemia, hypokalemia, hypercalcemia, and hypocalcemia.	Diagnosed through blood tests; treated by addressing underlying causes, dietary modifications, medications, or intravenous fluids and electrolytes.
<b>Dehydration</b>	Loss of water exceeds intake, leading to reduced total body water.	Causes include excessive sweating, vomiting, diarrhea, and inadequate fluid intake. Treatment involves rehydration through oral or intravenous fluids.
<b>Overhydration</b>	Excessive fluid intake or retention leading to increased total body water.	Causes include renal failure, heart failure, and excessive IV fluid administration. Treatment involves fluid restriction and addressing the underlying cause.
<b>Edema</b>	Excess fluid accumulation in the interstitial spaces.	Causes include increased capillary pressure, decreased plasma protein levels, increased capillary permeability, and lymphatic obstruction. Treatment involves addressing the underlying cause.

## POTASSIUM AND CALCIUM




Fig. (1). Potassium and calcium.

**CHAPTER 8****Gastrointestinal and Pancreatic Disease**

**Abstract:** The field of gastrointestinal and pancreatic diseases encompasses a wide range of conditions that have significant clinical implications. This chapter delves into the biochemical and physiological aspects of the Gastrointestinal (GI) tract and pancreas, offering insights into the pathophysiology, diagnosis, and management of common disorders such as inflammatory bowel disease, pancreatitis, and pancreatic cancer. Recent advancements in laboratory medicine, including the utilization of specific biomarkers, have led to improved diagnostic accuracy and therapeutic strategies. The emphasis is on integrating laboratory results with clinical findings to improve patient outcomes.

**LEARNING OBJECTIVES**

After reading this chapter, one should:

1. Be able to provide a general overview and describe the functions of the gastrointestinal and pancreatic systems.
2. Be able to describe diseases of gastrointestinal and pancreatic function.
3. Be able to recognize the causes, clinical signs, and symptoms of the following disorders relating to gastrointestinal and pancreatic function.
4. Be able to describe which laboratory investigations are important in the detection, diagnosis, and management of gastrointestinal and pancreatic diseases.
5. Be able to describe the following specific laboratory investigations important to the study of disorders of gastrointestinal and pancreatic function.
6. Be able to describe analytical methods available for their measurement.
7. Be able to select laboratory investigations and interpret the analytical results in the context of clinical signs and symptoms.

**KEY CONCEPTS: GASTROINTESTINAL AND PANCREATIC SYSTEMS**

**Functions of the Gastrointestinal and Pancreatic Systems (Table 1-4; Fig. 1, Fig. 2). [1, 2]**

**Table 1. Functions of the gastrointestinal and pancreatic systems.**

<b>System Component</b>	<b>General Overview</b>	<b>Functions</b>
<b>Mouth</b>	Entry point of the GI system	Mechanical breakdown of food (chewing) and enzymatic digestion (saliva).
<b>Esophagus</b>	A muscular tube connecting the mouth to the stomach	Transports food <i>via</i> peristalsis.
<b>Stomach</b>	A muscular organ that mixes food with gastric juices	Protein digestion, food conversion to chyme, secretion of hydrochloric acid, and digestive enzymes.
<b>Small Intestine</b>	A long, coiled tube divided into the duodenum, jejunum, and ileum	A major site for digestion and nutrient absorption, the secretion of digestive enzymes, and bile interaction.
<b>Large Intestine</b>	Shorter, wider tube connected to the small intestine	Absorbs water and electrolytes, forms and expels feces.
<b>Rectum and Anus</b>	Terminal parts of the GI system	Store and control expulsion of feces.
<b>Pancreas</b>	Gland with both endocrine and exocrine functions	Exocrine: Produces digestive enzymes and bicarbonate for digestion. Endocrine: Produces hormones (insulin, glucagon) to regulate blood glucose.

### **KEY CONCEPTS: INTESTINAL ABSORPTION OF PROTEINS, FATS, AND CARBOHYDRATES**

**Table 2. Functions of the gastrointestinal and pancreatic systems.**

<b>Nutrient</b>	<b>Digestive Process</b>	<b>Absorption Mechanism</b>	<b>Transport Pathway</b>	<b>Key Enzymes and Components</b>
<b>Proteins</b>	Proteins are broken down into peptides and amino acids	Amino acids and small peptides are absorbed primarily through active transport and facilitated diffusion	Amino acids and peptides enter the enterocytes (intestinal cells) and are then transported into the bloodstream <i>via</i> the portal vein to the liver	Pepsin (stomach), trypsin, chymotrypsin, carboxypeptidase (pancreas), and peptidases (small intestine)

(Table 2) cont....

Nutrient	Digestive Process	Absorption Mechanism	Transport Pathway	Key Enzymes and Components
<b>Fats</b>	Fats are emulsified by bile salts and digested into fatty acids and monoglycerides	Fatty acids and monoglycerides form micelles with bile salts, which diffuse into enterocytes. Inside enterocytes, they are re-esterified to form triglycerides and packaged into chylomicrons	Chylomicrons enter the lymphatic system <i>via</i> lacteals and eventually enter the bloodstream. Short- and medium-chain fatty acids are absorbed directly into the bloodstream	Lipase (pancreas), bile salts (liver), and colipase (pancreas)
<b>Carbohydrates</b>	Carbohydrates are broken down into monosaccharides (glucose, fructose, galactose)	Monosaccharides are absorbed through active transport (glucose and galactose <i>via</i> SGLT1) and facilitated diffusion (fructose <i>via</i> GLUT5)	Monosaccharides enter enterocytes and are then transported into the bloodstream <i>via</i> the portal vein to the liver	Amylase (saliva and pancreas), maltase, sucrase, and lactase (small intestine)

### KEY CONCEPTS: ENDOCRINE AND EXOCRINE FUNCTIONS OF THE PANCREAS [3, 4]

Table 3. Functions of the pancreatic systems.

Function	Component	Hormones/Enzymes	Primary Actions	Regulation and Control
<b>Endocrine</b>	Islets of Langerhans	<b>Insulin</b>	Lowers blood glucose by promoting cellular glucose uptake, glycogenesis, and lipogenesis	Stimulated by high blood glucose levels (hyperglycemia)
		<b>Glucagon</b>	Raises blood glucose by stimulating glycogenolysis and gluconeogenesis	Stimulated by low blood glucose levels (hypoglycemia)
		<b>Somatostatin</b>	Inhibits the release of both insulin and glucagon and slows down digestive processes	Regulated by blood glucose levels and other hormones
		<b>Pancreatic Polypeptide</b>	Regulates pancreatic secretions and influences hepatic glycogen levels	Regulated by food intake, blood glucose levels, and the autonomic nervous system

## Hepatobiliary Disease

**Abstract:** Hepatobiliary diseases encompass a wide range of conditions affecting the liver, gallbladder, and bile ducts, with significant clinical implications. This chapter explores the biochemical and physiological aspects of the hepatobiliary system, providing insights into the pathophysiology, diagnosis, and management of common disorders such as hepatitis, cirrhosis, and biliary obstruction. Advances in laboratory medicine, including the use of specific biomarkers, have improved diagnostic accuracy and therapeutic strategies. Emphasis is placed on integrating laboratory results with clinical findings to enhance patient outcomes.

**Keywords:** Biliary, Biliary obstruction, Cirrhosis, Hepatic, Hepatitis.

### LEARNING OBJECTIVES

After reading this chapter, one should be able to:

1. Be able to describe the physiological and biochemical functions of the hepatobiliary system and the pathophysiological mechanisms underlying common hepatobiliary diseases.
2. Be able to describe the causes, clinical signs, and symptoms of various disorders related to hepatobiliary function.
3. Be able to describe how laboratory investigations are important in the detection, diagnosis, and management.
4. Be able to describe specific laboratory investigations important to the study of disorders of hepatobiliary function.
5. Be able to recognise analytical methods available for their measurement.
6. Be able to select laboratory investigations and interpret the analytical results in the context of clinical signs and symptoms.

**KEY CONCEPTS: METABOLIC FUNCTIONS OF THE LIVER****Physiological and Biochemical Functions of Hepatobiliary System  
(Tables 1, 2) [1-4]****Table 1. Physiological and biochemical functions of the hepatobiliary system.**

Function	Processes
<b>Synthesis</b>	<b>Protein Synthesis:</b> Albumin, clotting factors, various enzymes <b>Lipid Metabolism:</b> Lipoproteins, cholesterol, phospholipids <b>Carbohydrate Metabolism:</b> Glycogenesis, glycogenolysis, gluconeogenesis <b>Bile Production:</b> Emulsification and absorption of dietary fats
<b>Conjugation</b>	<b>Bilirubin Conjugation:</b> Conjugation of bilirubin with glucuronic acid for excretion in bile <b>Drug Metabolism:</b> Drugs and toxins become more water-soluble compounds <b>Hormone Metabolism:</b> Conjugation and inactivation of hormones (thyroid, steroid)
<b>Detoxification</b>	<b>Ammonia Detoxification:</b> Toxic ammonia converted to urea <b>Toxin and Drug Metabolism:</b> Detoxification of alcohol, drugs, and environmental toxins through Phase I and II xenobiotic metabolism

**Table 2. Bilirubin.**

Stage	Processes
<b>Origin</b>	<b>Heme Breakdown:</b> Breakdown of heme produces bilirubin <b>Formation of Unconjugated Bilirubin:</b> Heme converts into biliverdin and finally produces unconjugated bilirubin
<b>Metabolism</b>	<b>Transport to Liver:</b> Unconjugated bilirubin is transported bound to albumin <b>Conjugation in Liver:</b> Bilirubin is conjugated with glucuronic acid by UDP-glucuronosyltransferase
<b>Transport and Excretion</b>	<b>Biliary Excretion:</b> Conjugated bilirubin is excreted into bile and transported to the small intestine <b>Intestinal Metabolism:</b> Conjugated bilirubin is converted into urobilinogen by bacterial enzymes and excreted in feces as stercobilin <b>Urinary Excretion:</b> Some urobilinogen is reabsorbed; the rest is excreted in urine as urobilin

**KEY CONCEPTS: ORIGIN, METABOLISM, AND TRANSPORT OF BILIRUBIN****Biochemical Basis, Relevant Lab Tests, Interpretation, and Applied Aspects***Biochemical Aspects of Hepatobiliary Disease*

Biochemical Basis, Relevant Lab Tests, Interpretation and Applied Aspects of

Hepatobiliary Disease (Tables 3-5; Figs. 1-4) [1-4].

**Table 3. Biochemical aspects of hepatobiliary disease.**

<b>Disease</b>	<b>Biochemical Aspects</b>
<b>Autoimmune Disease</b>	<b>Primary Biliary Cholangitis (PBC):</b> Elevated Alkaline Phosphatase (ALP) and Antimitochondrial Antibodies (AMA) <b>Autoimmune Hepatitis (AIH):</b> Elevated transaminases (ALT, AST), hypergammaglobulinemia, positive Antinuclear Antibodies (ANA), and Anti-Smooth Muscle Antibodies (ASMA)
<b>Cholestasis</b>	<b>Biochemical Indicators:</b> Elevated ALP and Gamma-Glutamyl Transferase (GGT), increased conjugated bilirubin, decreased bile acid secretion, leading to jaundice and pruritus.
<b>Drugs – Acute and Chronic</b>	<b>Acute Drug-Induced Liver Injury (DILI):</b> Elevated ALT, AST, and sometimes ALP, with possible hyperbilirubinemia <b>Chronic DILI:</b> Persistent mild elevations of liver enzymes, potential progression to fibrosis or cirrhosis
<b>Genetic (e.g., A1AT Deficiency)</b>	<b>Alpha-1 Antitrypsin (A1AT) Deficiency:</b> Low serum A1AT levels, accumulation of abnormal A1AT in hepatocytes, leading to elevated transaminases and risk of cirrhosis
<b>Inflammatory and Infective Liver Disease (Hepatitis)</b>	<b>Viral Hepatitis:</b> Elevated ALT, AST, and bilirubin levels, positive serological markers (HBsAg, anti-HCV) <b>Inflammatory Hepatitis:</b> Elevated inflammatory markers (CRP, ESR), and liver enzymes.
<b>Liver Autoantibodies</b>	<b>Autoimmune Hepatitis:</b> Positive ANA, ASMA, and liver/kidney microsomal antibodies (anti-LKM) <b>PBC:</b> Positive AMA
<b>Liver Cirrhosis</b>	<b>Biochemical Indicators:</b> Elevated bilirubin, prolonged Prothrombin Time (PT), low albumin, elevated liver enzymes (ALT, AST), and increased gamma-globulins.
<b>Liver Transplantation</b>	<b>Pre-Transplant:</b> Elevated liver enzymes, bilirubin, and markers of liver function (albumin, PT) <b>Post-Transplant:</b> Monitoring of liver enzymes, bilirubin, immunosuppressant levels, and signs of rejection or infection
<b>Liver Tumors – Primary or Secondary</b>	<b>Primary Liver Cancer (Hepatocellular Carcinoma):</b> Elevated Alpha-Fetoprotein (AFP), abnormal Liver Function Tests (LFTs), and imaging findings <b>Secondary (Metastatic) Liver Cancer:</b> Elevated liver enzymes, abnormal imaging, and tumor markers related to the primary cancer

## Immunology

**Abstract:** Immunology stands as a dynamic and intricate field with a pivotal role in understanding and addressing a diverse array of diseases. This chapter presents an in-depth exploration of the essential principles of immunology, encompassing both innate and adaptive immune responses. Furthermore, it delves into the intricacies of immune tolerance and autoimmunity. The ongoing evolution of immunological assays has significantly enhanced the diagnosis and management of immunological disorders, furnishing indispensable insights into patient care. The integration of immunological data with clinical findings is imperatively emphasized to bolster therapeutic strategies and improve patient outcomes.

### LEARNING OBJECTIVES

After reading the chapter, students should be able to:

- Describe the principles, components, and control of the immune system.
- Describe the causes, clinical signs, and symptoms of disorders of the immune system.
- Describe how laboratory investigations are important in the detection, diagnosis, and management.
- Describe specific laboratory investigations important in their detection, diagnosis, and management.
- Recognize analytical methods available for their measurement.
- Select laboratory investigations and interpret the analytical results in the context of clinical signs and symptoms.

### KEY CONCEPTS: BASICS, COMPONENTS, AND CONTROL OF THE IMMUNE SYSTEM

**Principles, Components and Control of the Immune System (Tables 1-4) [1 - 4]**

Table 1. Components of the immune system.

Concept	Description
<b>Immune System</b>	A defense system against pathogens, comprising various organs, cells, and molecules
<b>Innate Immunity</b>	A non-specific defense system present from birth It includes physical barriers and immune cells ( <i>e.g.</i> , macrophages and neutrophils)
<b>Adaptive Immunity</b>	Specific defense mechanisms that develop throughout life It involves T and B lymphocytes and provides long-term immunity
<b>Antigens</b>	Molecules (often from pathogens) that trigger an immune response by binding to specific antibodies or T-cell receptors
<b>Antibodies</b>	Proteins produced by B cells that neutralize pathogens or mark them for destruction by other immune cells
<b>T Cells</b>	Lymphocytes that mature in the thymus They play a role in directly killing infected cells (cytotoxic T cells) or coordinating immune responses (helper T cells)
<b>B Cells</b>	Lymphocytes that mature in bone marrow and produce antibodies specific to antigens encountered
<b>Major Histocompatibility Complex (MHC)</b>	Proteins that display antigens on cell surfaces for recognition by T cells These are crucial for immune response coordination
<b>Cytokines</b>	Signaling molecules secreted by immune cells that regulate inflammation, immune cell proliferation, and responses to infection
<b>Immune response</b>	A coordinated series of steps by the immune system to eliminate pathogens and restore homeostasis
<b>Immune tolerance</b>	Mechanisms that prevent the immune system from attacking the body's own cells and tissues
<b>Immunological memory</b>	The ability of the immune system to remember previous encounters with specific antigens, enabling faster and more effective responses upon re-exposure

**KEY CONCEPTS: COMPONENTS OF IMMUNE SYSTEM: CELLS, LYMPHOID TISSUE, SOLUBLE COMPONENTS, AND MEDIATORS**

Table 2. Components and mediators of the immune system.

Component	Description	Applied Aspects
<b>Cells</b>	Lymphocytes (T cells, B cells), macrophages, dendritic cells, neutrophils, and natural killer cells	<p><b>-Lymphocytes:</b> Adaptive immunity, memory response</p> <p><b>-Macrophages:</b> Phagocytosis, antigen presentation</p> <p><b>-Dendritic Cells:</b> Antigen presentation, activation of T cells</p> <p><b>-Neutrophils:</b> Phagocytosis, inflammation</p> <p><b>-Natural Killer Cells:</b> Attack virus-infected and tumor cells</p>
<b>Lymphoid Tissue</b>	Lymph nodes, spleen, tonsils, and Mucosa-Associated Lymphoid Tissue (MALT)	<p><b>-Lymph Nodes:</b> Filter lymph, activate immune response</p> <p><b>-Spleen:</b> Filters blood, immune responses to blood-borne pathogens</p> <p><b>-MALT:</b> Protects mucosal surfaces, initial immune response</p>
<b>Soluble Components</b>	Antibodies (immunoglobulins), complement proteins, cytokines (interleukins, interferons), and chemokines.	<p><b>-Antibodies:</b> Neutralization, opsonization, complement activation</p> <p><b>-Complement Proteins:</b> Membrane attack complex, inflammation</p> <p><b>-Cytokines:</b> Cell signaling, immune response modulation</p> <p><b>-Chemokines:</b> Cell migration, inflammation</p>
<b>Mediators</b>	Histamine, prostaglandins, leukotrienes, and nitric oxide that regulate inflammation, vascular permeability, and other immune responses	<p><b>-Histamine, Prostaglandins, Leukotrienes:</b> Vasodilation, inflammation</p> <p><b>-Nitric Oxide:</b> Antimicrobial activity, vasodilation</p>

## KEY CONCEPTS: IMMUNE CELLS

Table 3. Components of the immune system: cells.

Concept	Description	Applied Aspects
<b>Innate Immune System</b>	Non-specific defense mechanisms that provide immediate protection against pathogens, including physical barriers and immune cells like macrophages and neutrophils.	<p><b>-Infection Control:</b> Recognizing and responding to pathogens quickly. -</p> <p><b>Inflammation Regulation:</b> Understanding innate immune responses in diseases like sepsis</p>

## **Inborn Errors of Metabolism**

**Abstract:** Inborn Errors of Metabolism (IEMs) are a diverse group of genetic disorders resulting from defects in metabolic pathways. These disorders can lead to the accumulation of toxic substances or the deficiency of critical compounds, manifesting in a wide range of clinical symptoms. This chapter overviews the biochemical mechanisms underlying IEMs, highlights key diagnostic laboratory tests, and examines therapeutic approaches.

### **LEARNING OBJECTIVES**

After reading this chapter, one should be able to:

- Understand the biochemical basis and pathophysiology of common Inborn Errors of Metabolism (IEMs).
- Identify the clinical manifestations and diagnostic criteria for IEMs.
- Evaluate the role of laboratory tests in the diagnosis, monitoring, and management of IEMs.
- Explore current and emerging therapeutic strategies for managing IEMs.
- Discuss the genetic basis and inheritance patterns of IEMs.

**KEY CONCEPTS: *CHALLENGES WITH NEWBORN SCREENING.***

**Biochemical Basis and Pathophysiology of Common Inborn Errors of Metabolism (IEMs) (Table 1) [1 - 4]**

Table 1. Biochemical basis and pathophysiology of common inborn errors of metabolism.

Key Concept	Description
<b>Rationale for Screening</b>	Early identification of metabolic disorders to prevent severe complications through timely intervention.
<b>Overview of the Process</b>	Newborn screening involves blood tests, typically using a heel prick, to detect specific metabolic disorders. Early diagnosis facilitates early treatment, reducing morbidity and mortality.
<b>Challenges with Newborn Screening</b>	<p>Technical Challenges: Ensuring the accuracy and reliability of tests</p> <p>Logistical Challenges: Implementing efficient sample collection and processing</p> <p>Ethical and Legal Challenges: Addressing consent, privacy, and potential for false positives/negatives</p> <p>Includes false positives/negatives, limited availability of tests for all IEMs, variability in screening protocols, and the need for confirmatory testing.</p>
<b>Diseases Appropriate for Newborn Screening</b>	<p>Characteristics:</p> <p>- Prevalence: Sufficiently common to justify screening - Seriousness: Causes significant morbidity/mortality if untreated - Treatability: Effective treatment or intervention available - Detectability: Reliable, timely, and cost-effective test available.</p>
<b>Newborn Screening Process</b>	<p>Steps Involved:</p> <ul style="list-style-type: none"> <li>- Sample Collection: Blood sample typically collected <i>via</i> heel prick</li> <li>- Laboratory Analysis: Samples analyzed using various biochemical and genetic tests</li> <li>- Result Reporting: Timely reporting of results to healthcare providers and families</li> <li>- Follow-Up: Immediate follow-up for positive or ambiguous results to confirm diagnosis and initiate treatment.</li> </ul>

**KEY CONCEPTS: DISEASES APPROPRIATE FOR NEWBORN SCREENING – CHARACTERISTICS (TABLE 2)**

Table 2. Clinical manifestations and diagnostic criteria for IEMs.

Key Concept	Applied Aspects
Rationale for Screening and Overview	<ul style="list-style-type: none"> <li>- Early Detection: Identifying congenital disorders early to prevent severe health problems and improve outcomes</li> <li>- Cost-Effectiveness: Reducing long-term healthcare costs by preventing complications</li> <li>- Public Health Impact: Improving overall public health by addressing common congenital disorders early.</li> </ul>

Key Concept	Applied Aspects
Challenges with Newborn Screening	<ul style="list-style-type: none"> <li>- Technical Challenges: Ensuring the accuracy and reliability of screening tests; maintaining quality control</li> <li>- Logistical Challenges: Efficient sample collection, handling, and processing; timely reporting of results</li> <li>- Ethical and Legal Challenges: Addressing issues related to informed consent, data privacy, and potential psychological impact on families.</li> </ul>
Diseases Appropriate for Newborn Screening	<ul style="list-style-type: none"> <li>- Prevalence: Disorders must be sufficiently common to justify population-wide screening</li> <li>- Seriousness: Conditions that cause significant morbidity and mortality if untreated</li> <li>- Treatability: Availability of effective treatment or intervention that can significantly alter the course of the disease</li> <li>- Detectability: Reliable, timely, and cost-effective screening tests must be available.</li> </ul>
Newborn Screening Process	<ul style="list-style-type: none"> <li>- Sample Collection: Typically involves collecting a blood sample <i>via</i> heel prick</li> <li>- Laboratory Analysis: Use of biochemical and genetic tests such as tandem mass spectrometry, immunoassays, and molecular techniques</li> <li>- Result Reporting: Timely communication of results to healthcare providers and families</li> <li>- Follow-Up: Immediate follow-up for positive or ambiguous results to confirm diagnosis and initiate treatment.</li> </ul>

## BIOCHEMICAL BASIS, RELEVANT LAB TESTS, INTERPRETATION, AND APPLIED ASPECTS

### Role of Laboratory Tests in Diagnosis, Monitoring, and Management of IEMs (Tables 3,4) [1 - 4]

Table 3. Role of laboratory tests in diagnosis, monitoring, and management of IEMs.

Condition	Biochemical Basis	Relevant Lab Tests	Interpretation of Results	Applied Aspects
<b>Congenital Hypothyroidism</b>	Deficiency in thyroid hormone production due to thyroid gland dysgenesis or dyshormonogenesis.	TSH, Free T4, and Total T4	Elevated TSH and low Free T4/Total T4	Early treatment with thyroid hormone replacement to prevent intellectual disability.

## **Infectious Diseases**

**Abstract:** This chapter emphasises the practical applications of infectious diseases, highlighting the crucial role of laboratory diagnostics in detecting, managing, and monitoring infections. It addresses various types of infections, such as viral, bacterial, and parasitic diseases, providing in-depth information on the biochemical foundations, pertinent laboratory tests, and result interpretation. The goal is to offer clinical chemists the necessary knowledge to make meaningful contributions to patient care and public health efforts.

### **LEARNING OBJECTIVES**

After going through the chapter, one should be able to:

- Describe the role of laboratory testing in the diagnosis and monitoring of infectious diseases.
- Recommend and interpret laboratory tests for the diagnosis and management of infectious diseases.

### **KEY CONCEPTS *ROLE OF LABORATORY AND SEROLOGY TESTING IN DIAGNOSIS AND MONITORING OF INFECTIOUS DISEASE:***

**Role of Laboratory Testing in Diagnosis and Monitoring of Infectious Diseases (Tables 1,2) [1, 2]**

Table 1. Role of laboratory testing in diagnosis and monitoring of infectious diseases.

Key Concept	Explanation	Applied Aspects	Clinical Relevance
<b>Pathogenesis</b>	Study of how infectious agents cause disease	Understanding microbial mechanisms and host responses	Aids in developing targeted treatments and vaccines
<b>Microbial Identification</b>	Techniques for identifying infectious agents (bacteria, viruses, fungi, parasites)	Culture, PCR, serology, and MALDI-TOF MS	Critical for accurate diagnosis and appropriate treatment
<b>Antimicrobial Resistance</b>	Mechanisms by which microbes resist treatment	Antibiotic stewardship and resistance gene detection	Prevents treatment failure and informs antibiotic policy
<b>Diagnostic Testing</b>	Methods for detecting infectious agents or their effects	Blood tests, imaging, and molecular diagnostics	Essential for confirming diagnoses and guiding treatment
<b>Therapeutic Approaches</b>	Treatment options for infectious diseases	Antibiotics, antivirals, antifungals, and supportive care	Enhances patient outcomes and reduces morbidity and mortality

## DISEASE

### Relevant Laboratory Tests for Infectious Diseases for Detection, Diagnosis, Management, or Monitoring

Table 2. Role of laboratory testing in diagnosis and monitoring of infectious diseases.

Aspect	Description
<b>Biochemical Basis</b>	The biochemical basis of infectious diseases involves understanding the interaction between pathogens (bacteria, viruses, fungi, parasites) and the host's cellular and molecular mechanisms. This includes the ability of a pathogen to invade host tissues, evade the immune system, and produce toxins or other virulence factors that cause disease
<b>Relevant Laboratory Tests</b>	
<b>1. Blood Cultures</b>	To detect bacterial or fungal pathogens in the bloodstream
<b>2. Polymerase Chain Reaction (PCR)</b>	To identify specific genetic material from pathogens Useful for detecting viruses and bacteria
<b>3. Serology Tests</b>	To measure antibodies or antigens in blood to detect infections, <i>e.g.</i> , HIV, hepatitis, and syphilis
<b>4. Complete Blood Count (CBC)</b>	To assess the overall health of the blood, indicating infections through changes in white blood cells
<b>5. Urinalysis</b>	To detect pathogens or abnormalities in urine, indicating urinary tract infections

(Table 2) cont....

Aspect	Description
<b>6. Imaging Studies (X-ray, CT, MRI)</b>	Visualizes infections in organs and tissues
<b>7. Culture and Sensitivity</b>	Grows pathogens from samples ( <i>e.g.</i> , sputum, wound swabs) to identify the organism and test antibiotic susceptibility
<b>8. Rapid Antigen Tests</b>	Quickly detects specific antigens from pathogens ( <i>e.g.</i> , influenza, strep throat)
<b>Interpretation of Results:</b>	
<b>Positive Blood Cultures</b>	Indicates the presence of pathogens in the blood, suggesting sepsis or systemic infection
<b>PCR Results</b>	Positive results confirm the presence of the pathogen's genetic material, indicating an active infection
<b>Serology Tests</b>	Presence of specific antibodies indicates current or past infection; high levels of IgM suggest recent infection, while IgG suggests past exposure or immunity
<b>CBC Results</b>	Elevated white blood cell count (leukocytosis) typically indicates infection; specific patterns can suggest bacterial <i>vs.</i> viral infections
<b>Urinalysis</b>	Presence of bacteria, white blood cells, or nitrites indicates a urinary tract infection
<b>Imaging Studies</b>	Identifies structural abnormalities, abscesses, or inflammation associated with infections
<b>Culture and Sensitivity</b>	Identifies specific pathogens and guides appropriate antibiotic therapy based on susceptibility results
<b>Rapid Antigen Tests</b>	Positive results quickly confirm the presence of specific pathogens, allowing for timely treatment
<b>Applied Aspects:</b>	
<b>1. Diagnosis</b>	Accurate identification of the causative pathogen is crucial for effective treatment and management
<b>2. Treatment</b>	Laboratory results guide the choice of antimicrobial therapy, ensuring targeted and effective treatment
<b>3. Public Health</b>	Surveillance and monitoring of infectious diseases help in controlling outbreaks and implementing preventive measures
<b>4. Infection Control</b>	Identifying and isolating infectious patients prevents the spread of pathogens within healthcare settings
<b>5. Prognosis and Monitoring</b>	Regular monitoring of infection markers and response to treatment guides clinical decisions and improves patient outcomes

## CHAPTER 13

# Iron and Hemoglobin Disorders, Including Porphyrrias

**Abstract:** Understanding iron and hemoglobin disorders, such as porphyrias, is crucial for effective clinical diagnostics and management. This chapter provides in-depth insights into the biochemical foundations of these conditions, emphasizing the pivotal role of iron in the body, the genetic and molecular underpinnings of hemoglobinopathies, and the metabolic pathways associated with porphyrias. By examining pertinent laboratory tests and their interpretation, the chapter is designed to empower clinical chemists with the essential knowledge required for precise diagnosis and successful management of these disorders.

### LEARNING OBJECTIVES

After reading through this chapter, one should be able to:

1. Understand Iron Metabolism: Gain insight into the regulation of iron absorption, transport, storage, and its role in hemoglobin synthesis.
2. Identify Hemoglobin Disorders: Learn about various hemoglobinopathies, including sickle cell disease and thalassemia.
3. Explore the Biochemistry of Porphyrrias: Understand the biochemical basis of porphyrias and their clinical implications.
4. Interpret Diagnostic Tests: Develop skills in interpreting laboratory tests related to iron metabolism, hemoglobin disorders, and porphyrias.
5. Clinical Management: Understand the clinical management strategies for disorders of iron metabolism and hemoglobin, with a focus on therapeutic approaches.

## KEY CONCEPTS: IRON AND HEME METABOLISM AND THEIR REGULATION

### Regulation of Iron Absorption, Transport, Storage, and its Role in Hemoglobin Synthesis (Tables 1-3.1, 3.2) [1-5]

Table 1. Iron absorption, transport, storage, and its role in hemoglobin synthesis.

Concept	Details
<b>Iron Absorption</b>	Iron is absorbed primarily in the duodenum. Non-heme iron ( $\text{Fe}^{3+}$ ) is reduced to $\text{Fe}^{2+}$ by cytb and then transported into enterocytes by DMT1. Heme iron is directly absorbed <i>via</i> Heme Carrier Protein 1 (HCP1).
<b>Iron Transport</b>	Once in the enterocyte, iron can be stored as ferritin or exported to the bloodstream by ferroportin. In the blood, $\text{Fe}^{2+}$ is oxidized to $\text{Fe}^{3+}$ by hephaestin and ceruloplasmin, and then bound to transferrin for transport (Fig. 1).
<b>Iron Storage</b>	Iron is stored in the liver, spleen, and bone marrow in the form of ferritin and hemosiderin.
<b>Heme Synthesis</b>	Heme is synthesized in the mitochondria and cytosol of cells, primarily in the bone marrow and liver. The process involves eight enzymatic steps, starting with the condensation of glycine and succinyl-CoA to form $\delta$ -aminolevulinic acid (ALA).
<b>Heme Degradation</b>	Heme is degraded to biliverdin by heme oxygenase, then reduced to bilirubin. Bilirubin is transported to the liver, conjugated with glucuronic acid, and excreted in bile.
<b>Regulation of Iron Homeostasis</b>	Hepcidin, produced by the liver, is the key regulator. It binds to ferroportin, causing its internalization and degradation, thus reducing iron absorption and release from macrophages.
<b>Regulation of Heme Synthesis</b>	Heme synthesis is regulated primarily at the level of ALA synthase, which is inhibited by heme (negative feedback).

## KEY CONCEPTS: APPLIED ASPECTS OF IRON AND HEME METABOLISM

Table 2. Applied aspects of iron and heme metabolism.

Aspect	Details
<b>Dietary Iron Intake</b>	Iron can be obtained from dietary sources such as red meat (heme iron) and vegetables (non-heme iron). Vitamin C enhances non-heme iron absorption.
<b>Iron Supplementation</b>	Used to treat iron deficiency. Oral ferrous sulfate is common, but intravenous iron may be needed in severe cases.
<b>Phlebotomy</b>	Therapeutic phlebotomy is used to treat iron overload conditions such as hereditary hemochromatosis.

(Table 2) cont....

Aspect	Details
<b>Chelation Therapy</b>	Deferoxamine and other iron chelators are used to treat iron overload by promoting excretion.
<b>Monitoring Iron Levels</b>	Serum ferritin, transferrin saturation, and Total Iron-Binding Capacity (TIBC) are used to assess iron status.

Table 3.1. Applied aspects of iron metabolism.

Disorder	Biochemical Basis
<b>Iron Overload</b>	Excessive iron absorption or multiple blood transfusions lead to iron accumulation in tissues, causing oxidative damage and organ dysfunction. Heparin deficiency is a common cause of hereditary hemochromatosis.
<b>Iron Deficiency</b>	Insufficient iron intake, increased requirements (e.g., pregnancy), or chronic blood loss lead to reduced hemoglobin synthesis and microcytic hypochromic anemia.

## KEY CONCEPTS: BIOCHEMICAL BASIS OF IRON OVERLOAD AND IRON DEFICIENCY

### Implications of iron overload and iron deficiency

Table 3.2. Applied aspects of iron metabolism.

Disorder	Clinical Signs and Symptoms	Implications
<b>Iron Overload</b>	Fatigue, joint pain, abdominal pain, liver cirrhosis, diabetes, cardiomyopathy	Increased risk of liver cancer, diabetes, and heart disease. Requires regular monitoring and treatment to prevent organ damage.
<b>Iron Deficiency</b>	Fatigue, pallor, shortness of breath, dizziness, and pica	Reduced work capacity, impaired cognitive function, and increased risk of preterm birth in pregnant women. Requires dietary changes, supplementation, and treatment of underlying causes.

## **Lipids and Disorders of Lipoprotein Metabolism**

**Abstract:** Disorders of lipoprotein metabolism encompass a range of conditions that significantly contribute to cardiovascular diseases. These disorders are often characterized by abnormalities in the levels and composition of plasma lipids and lipoproteins. The clinical relevance of these disorders is underscored by their association with atherosclerosis, a leading cause of morbidity and mortality worldwide. This chapter delves into the biochemical underpinnings of lipid disorders, exploring the diagnostic tools and therapeutic approaches employed in clinical practice. By understanding these mechanisms, clinicians and laboratory professionals can improve patient outcomes through targeted interventions and personalized medicine approaches.

**Keywords:** Lipid disorders, Lipoprotein metabolism, Plasma lipids, Plasma lipoproteins.

### **LEARNING OBJECTIVES**

After going through the chapter, one should be able to:

- Describe the principles and control of lipid metabolism and key aspects of the study of lipid and lipoprotein disorders.
- Describe the causes, clinical signs, and symptoms of disorders relating to lipid and lipoprotein disorders.
- Describe biochemical and clinical laboratory methods for the detection, diagnosis, and management of disorders relating to lipid and lipoprotein disorders.
- Describe specific laboratory investigations important to the study of disorders of lipid and lipoprotein metabolism.
- Recognize analytical methods available for their measurement.
- Select laboratory investigations and interpret the analytical results in the context of clinical signs and symptoms.

**KEY CONCEPTS: LIPID METABOLISM AND ITS REGULATION****Principles and Control of Lipid Metabolism (Tables 1, 2)****Table 1. Lipid metabolism and lipoprotein disorders.**

<b>Key Concepts</b>	<b>Description</b>	<b>Applied Aspects</b>
<b>Overview of Lipid Metabolism</b>	Involves the synthesis, storage, and breakdown of lipids, including fatty acids, triglycerides, phospholipids, and cholesterol, in the body	For managing metabolic diseases, such as obesity, diabetes, and cardiovascular diseases
<b>Lipogenesis</b>	Process of fatty acid synthesis from acetyl-CoA and malonyl-CoA by the enzyme fatty acid synthase Occurs in the liver and adipose tissue	Serve as a target for dietary interventions, anti-obesity drugs
<b>Lipolysis</b>	Breakdown of triglycerides into free fatty acids and glycerol by hormone-sensitive lipase Occurs in adipose tissue	Enhancing lipolysis can be beneficial in weight loss strategies and in treating metabolic syndrome
<b>Beta-Oxidation</b>	Breakdown of fatty acids in mitochondria to generate acetyl-CoA and ATP	For energy production, particularly during fasting or prolonged exercise Defects can lead to metabolic disorders
<b>Ketogenesis</b>	Production of Ketone bodies (acetoacetate, beta-hydroxybutyrate, and acetone) from acetyl-CoA in liver during periods of low carbohydrate intake	Ketogenic diets utilize this pathway for weight loss and managing epilepsy Excessive ketogenesis can lead to ketoacidosis
<b>Cholesterol Metabolism</b>	Involves the synthesis, absorption, and elimination of cholesterol. Key pathways: mevalonate pathway and conversion of cholesterol to bile acids	Drug targets: statins and other cholesterol-lowering drugs to reduce cardiovascular disease risk
<b>Lipoprotein Metabolism</b>	Lipoproteins transport lipids in the blood, and each type has a specific role in lipid transport and metabolism: Includes chylomicrons, VLDL, LDL, and HDL (Fig. 1)	Alterations in lipoprotein metabolism are implicated in atherosclerosis Targets to modify lipoprotein levels and improve cardiovascular outcomes
<b>Regulation of Lipid Metabolism</b>	Regulation: Hormonal: insulin, glucagon, and epinephrine Dietary factors Genetic regulation ( <i>e.g.</i> , SREBP, PPARs)	Target for interventions: changes (diet, exercise) Pharmacological agents ( <i>e.g.</i> , fibrates, thiazolidinediones) Gene therapy approaches

(Table 1) cont....

Key Concepts	Description	Applied Aspects
<b>Fatty Acid Synthesis Pathway</b>	Key enzymes: Acetyl-CoA Carboxylase (ACC) and Fatty Acid Synthase (FAS) Upregulated in the fed state Downregulated in the fasting state	Target for anti-obesity and anti-cancer drugs
<b>Fatty Acid Oxidation Pathway</b>	Key regulatory enzyme: Palmitoyl transferase I (CPT1): Controls the entry of fatty acids into mitochondria for oxidation	Deficiencies can lead to fatty acid oxidation disorders Therapeutic targets: dietary management and enzyme replacement therapies
<b>Triglyceride Storage and Mobilization</b>	Storage form in adipose tissue Mobilization regulated by hormonal signals: insulin and catecholamines	Important in energy balance and obesity Therapeutic target: interventions to manage excessive triglyceride storage or enhance mobilization in metabolic diseases
<b>Impact of Diet and Exercise</b>	Dietary intake of fats influences lipid metabolism Exercise increases fatty acid oxidation and improves lipid profile	Target for strategies in managing dyslipidemia and preventing cardiovascular diseases: Nutritional interventions and physical activity
<b>Genetic Factors in Lipid Metabolism</b>	Genetic variations ( <i>e.g.</i> , ApoE polymorphisms) affect lipid levels, posing the risk of cardiovascular diseases	Personalized treatment strategies for dyslipidemia and prevention of disease
<b>Pharmacological Regulation</b>	Drug target: Statins, fibrates, niacin, and omega-3 fatty acids are used to manage dyslipidemia Acts by various mechanisms to reduce LDL and VLDL and increase HDL	Management of hyperlipidemia Prevention of atherosclerotic cardiovascular disease
<b>Metabolic Syndrome and Lipid Metabolism</b>	Cluster of conditions: Insulin resistance, hypertension, and dyslipidemia Often associated with obesity	Target for comprehensive management: Includes lifestyle interventions, pharmacotherapy, and monitoring to reduce cardiovascular risk
<b>Non-Alcoholic Fatty Liver Disease (NAFLD)</b>	Excessive accumulation of fat in the liver, not due to alcohol consumption Often associated with obesity, diabetes, and metabolic syndrome	Target management includes weight loss, insulin sensitizers, and lipid-lowering agents Prevention focuses on lifestyle modifications

## CHAPTER 15

# Minerals: Calcium, Magnesium, Parathyroid, Bone Disorders

**Abstract:** Calcium and magnesium play essential roles in neuromuscular function, bone health, and metabolic processes, and are regulated by hormones such as Parathyroid Hormone (PTH) and vitamin D. Dysregulation of these minerals can lead to disorders such as hypocalcemia, hypercalcemia, hypomagnesemia, and bone-related conditions like osteoporosis and Paget's disease. This paper explores the applied clinical chemistry aspects of mineral metabolism, focusing on diagnostic methods, interpretation of lab results, and treatment options for calcium, magnesium, and bone disorders.

**Keywords:** Bone disorders, Calcium, Magnesium, Parathyroid hormone, Vitamin D.

### LEARNING OBJECTIVES

After reading this chapter, one should be able to:

- Describe the control of calcium and phosphate homeostasis.
- Describe the causes, clinical signs, and symptoms of the disorders and manifestations of calcium and phosphate metabolism and bone disease.
- Describe how laboratory investigations are important in their detection, diagnosis, and management.
- Describe the specific laboratory investigations important to studying calcium and phosphate metabolism and bone disease.
- Recognize the analytical methods available for their measurement.
- Select laboratory investigations and interpret the analytical results in the context of clinical signs and symptoms.

**KEY CONCEPTS: CALCIUM AND PHOSPHATE HOMEOSTASIS****Control of Calcium and Phosphate Homeostasis (Table 1)****Table 1. Control of calcium and phosphate homeostasis.**

<b>Mineral</b>	<b>Key Concepts</b>	<b>Applied Aspects</b>
Calcium	<p>Circulating forms of calcium:</p> <ul style="list-style-type: none"> <li>- Ionized Calcium (50%): Active form, free in plasma.</li> <li>- Protein-bound Calcium (40%): Mostly bound to albumin.</li> <li>- Complexed Calcium (10%): Bound to anions like phosphate.</li> </ul>	<ul style="list-style-type: none"> <li>- Ionized calcium: Physiologically active form Crucial for: muscle contraction nerve conduction clotting</li> <li>- Protein-bound calcium: levels are affected by albumin concentration, making correction important in hypoalbuminemia.</li> </ul>
Vitamin D	<ul style="list-style-type: none"> <li>- Vitamin D3 (cholecalciferol): Synthesized in the skin from sunlight.</li> <li>- Hydroxylation in the liver produces 25-hydroxyvitamin D.</li> <li>- Kidney hydroxylation forms active 1,25-dihydroxyvitamin D (calcitriol).</li> </ul>	<ul style="list-style-type: none"> <li>- Calcitriol: Increases calcium and phosphate absorption in the intestines and regulates bone resorption.</li> <li>- Deficiency causes rickets in children and osteomalacia in adults.</li> <li>- Lab assays: Measure 25(OH)D to assess vitamin D status.</li> </ul>
Markers of Bone Resorption and Formation	<ul style="list-style-type: none"> <li>- Bone Resorption Markers: CTX (C-terminal telopeptide), NTX (N-terminal telopeptide), and TRAP (tartrate-resistant acid phosphatase).</li> <li>- Bone Formation Markers: ALP (alkaline phosphatase), P1NP (procollagen type I N-terminal propeptide), and osteocalcin.</li> </ul>	<ul style="list-style-type: none"> <li>- Elevated bone resorption markers indicate conditions: Osteoporosis and Paget's disease.</li> <li>- Bone formation markers: Elevated in growing children, healing fractures, and bone metabolic diseases.</li> <li>- Used to monitor response to therapies.</li> </ul>
Disorders of calcium homeostasis	<ul style="list-style-type: none"> <li>- Primary Hypercalcemia: Caused by conditions like hyperparathyroidism (increased PTH).</li> <li>- Secondary Hypercalcemia: Due to extrinsic factors: excessive vitamin D or malignancies.</li> <li>- Primary Hypocalcemia: Result of insufficient PTH (e.g., hypoparathyroidism).</li> <li>- Secondary Hypocalcemia: Caused by: Chronic kidney disease, leading to impaired vitamin D metabolism.</li> </ul>	<ul style="list-style-type: none"> <li>- Diagnosis: Measurement of PTH, calcium, phosphate, and vitamin D levels.</li> <li>- Primary Hypercalcemia: Managed by parathyroidectomy or medications.</li> <li>- Secondary Hypercalcemia: Treated by addressing the underlying cause (e.g., cancer, vitamin D toxicity).</li> </ul>

(Table 1) cont....

Mineral	Key Concepts	Applied Aspects
Calcium and phosphate homeostasis	<ul style="list-style-type: none"> <li>- Regulated by: Parathyroid Hormone (PTH), vitamin D, and calcitonin.</li> <li>- PTH: Increases calcium reabsorption in the kidneys, stimulates bone resorption, and activates vitamin D.</li> <li>- Vitamin D (calcitriol): Increases intestinal absorption of calcium and phosphate.</li> <li>- Calcitonin: Lowers blood calcium by inhibiting bone resorption.</li> </ul>	<ul style="list-style-type: none"> <li>- PTH and vitamin D work in concert to maintain calcium homeostasis.</li> <li>- Disorders, namely hypoparathyroidism, vitamin D deficiency, or chronic kidney disease, disrupt this regulation.</li> <li>- Correcting imbalances may involve supplementation or hormone therapy.</li> </ul>

### Biochemical Basis, Relevant Lab Tests, Interpretation, and Applied Aspects

#### Laboratory Investigations in Detection, Diagnosis, and Management of Disorders (Table 2)

Table 2. Biochemical basis, relevant lab tests, interpretation, and applied aspects.

Condition	Biochemical Basis	Relevant Lab Tests	Interpretation of Results	Applied Aspects
Hypercalcemia	Excess calcium in the blood due to increased bone resorption, excessive vitamin D, or PTH production.	Serum calcium (total/ionized), PTH, vitamin D, phosphate, and ALP	Elevated calcium, high or low PTH, low phosphate, and high ALP in bone-related causes	Requires differentiation between primary hyperparathyroidism, malignancy, and vitamin D toxicity. Treatment depends on the underlying cause.
Hypermagnesemia	Excess magnesium due to renal failure, excessive intake of magnesium supplements, or drugs.	Serum magnesium, calcium, PTH, and kidney function tests	Elevated magnesium, potential hypocalcemia	Often seen in renal failure or patients receiving magnesium-based treatments. Treated by restricting intake or dialysis.
Hyperparathyroidism	Overproduction of PTH, leading to increased calcium and decreased phosphate levels.	Serum calcium, PTH, phosphate, ALP, and vitamin D	Elevated calcium, high PTH, and low phosphate	Primary hyperparathyroidism, treated with surgery; secondary hyperparathyroidism, managed by treating the underlying cause (e.g., CKD).

---

## Musculoskeletal Diseases

**Abstract:** Musculoskeletal diseases impact bone metabolism and function. This chapter discusses the role of biochemistry in diagnosing and managing these diseases, emphasizing the importance of early diagnosis through biochemical testing to prevent severe complications such as fractures or deformities.

### LEARNING OBJECTIVES

After reading this chapter, one should be able to:

- Discuss muscle function and the use and limitations of autoimmune testing in diagnosis.
- Discuss the causes, clinical signs, and symptoms of musculoskeletal disorders
- Describe how laboratory investigations are important in their detection, diagnosis, and management.
- Describe the specific laboratory investigations used in the management of musculoskeletal diseases.
- Recognize the analytical methods available for their measurement.
- Select laboratory investigations and interpret the analytical results in the context of the clinical signs and symptoms.

**KEY CONCEPTS: APPLIED ASPECTS OF MUSCLE FUNCTION****Muscle Function and the Use of Autoimmune Testing in Diagnosis (Table 1,2) [1 - 4]**

Table 1. Muscle functions and applied aspects.

Aspect	Details
Key Concepts	<p><b>-Muscle Types:</b> Skeletal, cardiac, and smooth muscle</p> <p><b>-Muscle Contraction:</b> Sliding filament theory involving actin and myosin</p> <p><b>-Energy Sources:</b> ATP, creatine phosphate, glycolysis, and oxidative phosphorylation</p> <p><b>-Neuromuscular Junction:</b> Transmission of nerve impulses to muscles <i>via</i> the neurotransmitter acetylcholine</p> <p><b>-Muscle Fiber Types:</b> Slow-twitch (Type I) and fast-twitch (Type II) fibers.</p>
<i>Applied Aspects</i>	
Muscle Enzymes	<p>Creatine Kinase (CK):</p> <p>Key enzyme released during muscle damage <i>e.g.</i>, in rhabdomyolysis, muscular dystrophy</p> <p>CK levels are critical for diagnosing muscle injury or diseases. LDH and AST also rise in muscle damage, but are less specific.</p>
Diagnostic Tests	<p>Electromyography (EMG), muscle biopsy, and MRI to evaluate muscle function and structure.</p> <p>Biochemical markers (<i>e.g.</i>, CK, aldolase) complement these tests for muscle disease diagnosis.</p>
Applications	<p><b>-Exercise Physiology:</b> Understanding muscle function helps in designing training programs.</p> <p><b>-Rehabilitation:</b> Muscle function knowledge is crucial in physical therapy.</p> <p><b>-Sports Medicine:</b> Enhancing muscle performance and recovery.</p> <p><b>-Clinical Diagnostics:</b> Identifying muscle dysfunction in various diseases.</p>

Table 2. Autoimmune testing in the diagnosis of musculoskeletal diseases.

Key Concept	Diagnostic use	Limitations
<b>Antinuclear Antibodies (ANA)</b>	Screening test for systemic autoimmune diseases like Systemic Lupus Erythematosus (SLE), Sjogren's syndrome, and mixed connective tissue diseases.	High sensitivity but low specificity; positive results in healthy individuals, infections, or other non-autoimmune conditions.
<b>Anti-double-stranded DNA (Anti-dsDNA)</b>	Specific marker for SLE, particularly for assessing disease activity and lupus nephritis.	False positives may occur in chronic infections and other autoimmune diseases.
<b>Anti-Ro (SSA) and Anti-La (SSB) Antibodies</b>	Diagnosis of Sjögren's syndrome and neonatal lupus; also seen in SLE.	Can be present in other autoimmune conditions, leading to diagnostic confusion.

*(Table 2) cont....*

<b>Key Concept</b>	<b>Diagnostic use</b>	<b>Limitations</b>
<b>Anti-Sm Antibodies</b>	Highly specific for SLE; considered a confirmatory test.	Low sensitivity; found in only about 20-30% of SLE patients, thus may miss cases.
<b>Anti-cyclic citrullinated peptide (Anti-CCP)</b>	High specificity for Rheumatoid Arthritis (RA); helps in early diagnosis and predicting disease severity.	Can be negative in early stages of RA or in seronegative RA cases.
<b>Rheumatoid Factor (RF)</b>	Used in the diagnosis of RA, but can also be positive in other autoimmune conditions, infections, and aging.	Low specificity; can be positive in non-autoimmune diseases like chronic infections or in healthy elderly individuals.
<b>Anti-neutrophil cytoplasmic antibodies (ANCA)</b>	Useful in diagnosing vasculitis ( <i>e.g.</i> , granulomatosis with polyangiitis).	Limited by false positives in infections, drug-induced vasculitides, and other inflammatory conditions.
<b>Anti-thyroid peroxidase (Anti-TPO) and Anti-thyroglobulin (Anti-TG)</b>	Markers for autoimmune thyroid diseases like Hashimoto's thyroiditis and Graves' disease.	Antibodies may be present in euthyroid individuals or those with non-autoimmune thyroid conditions.
<b>Anti-Glutamic Acid Decarboxylase (GAD) Antibodies</b>	Diagnostic for Type 1 diabetes and some neurological conditions ( <i>e.g.</i> , stiff-person syndrome).	Can be found in other autoimmune conditions and healthy individuals, reducing specificity.
<b>Anti-Phospholipid Antibodies (APA)</b>	Helps diagnose antiphospholipid syndrome, which is associated with thrombosis and pregnancy complications.	Can be transiently positive in infections or drug reactions, requiring repeat testing for confirmation.
<b>Anti-Smooth Muscle Antibodies (ASMA)</b>	Used in the diagnosis of autoimmune hepatitis.	Low specificity; may be positive in viral hepatitis or other liver diseases.
<b>Anti-Mitochondrial Antibodies (AMA)</b>	Highly specific for Primary Biliary Cholangitis (PBC).	Low sensitivity; not present in all cases of PBC, potentially missing some diagnoses.
<b>Anti-parietal Cell Antibodies</b>	Associated with autoimmune gastritis and pernicious anemia.	Positive results are seen in other conditions, including aging or in individuals without clinical disease.

## **KEY CONCEPTS: USE AND LIMITATIONS OF AUTOIMMUNE TESTING IN DIAGNOSIS**

### **Disease**

#### ***Biochemical Basis, Relevant Lab Tests, Interpretation of Results***

---

## Neurological and Psychiatric Disorders

**Abstract:** Neurological and psychiatric disorders are complex conditions that involve the interplay of various biochemical pathways. This study guide focuses on the applied aspects of clinical chemistry in diagnosing and managing these disorders. It covers the biochemical markers associated with different neurological and psychiatric conditions, the laboratory techniques used to measure these markers, and the interpretation of results in a clinical context. The guide also highlights the importance of a multidisciplinary approach and ethical considerations in the biochemical assessment of these disorders.

### LEARNING OBJECTIVES

After reading this chapter, one should be able to:

- Discuss the biochemical basis and clinical manifestations of neurological and psychiatric disorders.
- Discuss the causes, clinical signs, and symptoms of the following disorders, some of which are primary neurological disorders and some of which have neurological manifestations.
- Describe which laboratory investigations are important in their detection, diagnosis, and management.
- Discuss the following specific laboratory investigations related to the study of neurological disorders.
- Recognise the analytical methods available for their measurement.
- Select laboratory investigations and interpret the analytical results in the context of the clinical signs and symptoms.

**KEY CONCEPTS****Biochemical Basis and Clinical Manifestations of Neurological and Psychiatric Disorders (Tables 1 and 2) [1 - 3]****Table 1. Blood-Brain Barrier (BBB).**

Aspect	Details
<b>Key Concepts</b>	<p><b>-Structure:</b> The BBB is formed by endothelial cells of brain capillaries, tightly joined by tight junctions, along with astrocyte end-feet and pericytes</p> <p><b>Function:</b> The BBB regulates the passage of substances from the bloodstream into the brain, protecting the CNS from toxins and pathogens while allowing essential nutrients to pass</p>
<b>Physiological Roles</b>	<p><b>-Protection:</b> Shields the brain from harmful substances and pathogens</p> <p><b>-Homeostasis:</b> Maintains a stable environment for neuronal function</p> <p><b>-Selective Permeability:</b> Allows the passage of essential molecules like glucose and amino acids while restricting harmful substances</p>
<b>Pathophysiology</b>	<p><b>-Disruption:</b> Conditions like multiple sclerosis, stroke, trauma, and infections can disrupt the BBB, leading to increased permeability and potential neuroinflammation</p> <p><b>-Inflammation and Autoimmunity:</b> Inflammatory cytokines can weaken BBB integrity, facilitating the entry of immune cells into the CNS</p>
<b>Clinical Applications</b>	<p><b>-Drug Delivery:</b> Challenges in delivering therapeutic agents to the brain due to the restrictive nature of the BBB</p> <p><b>-Biomarkers:</b> BBB integrity can be assessed through imaging techniques and Cerebrospinal Fluid (CSF) analysis</p> <p><b>-Therapies:</b> Research into methods to transiently open the BBB for drug delivery, such as focused ultrasound and chemical agents.</p>
<b>Research Directions</b>	<p><b>-Nanotechnology:</b> Development of nanoparticles to cross the BBB for targeted drug delivery</p> <p><b>-Molecular Mechanisms:</b> Understanding the molecular pathways regulating BBB function to develop strategies to protect or restore its integrity</p> <p><b>-Neurodegenerative Diseases:</b> Investigating the role of BBB dysfunction in diseases like Alzheimer's and Parkinson's.</p>

**Table 2. Paraneoplastic syndromes [1, 2].**

Aspect	Details
<b>Key Concepts</b>	<p><b>-Definition:</b> Paraneoplastic syndromes are a group of disorders that occur in patients with cancer, where symptoms are not directly related to tumor invasion or metastasis but are caused by immune-mediated mechanisms or hormone-like substances produced by the tumor</p> <p><b>-Mechanism:</b> Often involves immune cross-reactivity where the body's immune response against tumor antigens also targets similar antigens in the nervous system</p>

(Table 3) cont....

Aspect	Details
<b>Common Syndromes</b>	<p><b>-Neurological Paraneoplastic Syndromes:</b> Include Lambert-Eaton myasthenic syndrome, paraneoplastic cerebellar degeneration, opsoclonus-myoclonus syndrome, and limbic encephalitis</p> <p><b>-Symptoms:</b> Can vary widely but often include neurological deficits such as ataxia, myoclonus, encephalopathy, neuropathy, and autonomic dysfunction</p>
<b>Pathophysiology</b>	<p><b>-Autoantibodies:</b> Production of antibodies against neuronal antigens (e.g., Hu, Yo, Ri, Ma2) that are also expressed by the tumor</p> <p><b>-Immune Response:</b> Immune cells, such as T cells, may also play a role in the damage to the nervous system</p>
<b>Diagnostic Tests</b>	<p><b>-Autoantibody Testing:</b> Detection of specific paraneoplastic antibodies (e.g., anti-Hu, anti-Yo, anti-Ri) in serum or CSF</p> <p><b>-Imaging:</b> MRI may show characteristic changes depending on the affected CNS region</p> <p><b>-Tumor Screening:</b> Comprehensive screening to identify the underlying malignancy, including CT, PET scans, and tumor markers</p>
<b>Clinical Management</b>	<p><b>-Treating the Underlying Cancer:</b> Often the primary approach, as successful treatment of the cancer can lead to improvement of neurological symptoms</p> <p><b>-Immunotherapy:</b> Use of corticosteroids, IVIG, plasmapheresis, and other immunosuppressive therapies to reduce the autoimmune response</p> <p><b>-Symptomatic Treatment:</b> Management of specific symptoms and supportive care</p>
<b>Research Directions</b>	<p><b>-Immunopathogenesis:</b> Further understanding of the immune mechanisms leading to paraneoplastic syndromes</p> <p><b>-Biomarkers:</b> Identification of new biomarkers for early detection and better diagnosis</p> <p><b>-Therapeutic Strategies:</b> Development of targeted therapies to modulate the immune response without compromising anti-tumor immunity</p>

### Biochemical Basis, Relevant Lab Tests, Interpretation, and Applied Aspects

#### *Biochemical Basis, Relevant Lab Tests, Interpretation, and Applied Aspects of Neurological and Psychiatric Disorders (Tables 3-8)*

Table 3. Acute porphyrias.

Aspect	Details
<b>Biochemical Basis</b>	<b>-Metabolic Disorders:</b> Acute porphyrias are caused by defects in heme biosynthesis, leading to accumulation of porphyrin precursors.
<b>Types</b>	<b>-Acute Intermittent Porphyria (AIP), Variegate Porphyria (VP), Hereditary Coproporphyrinuria (HCP).</b>
<b>Symptoms</b>	<b>-Acute Attacks:</b> Abdominal pain, neurological symptoms, and psychiatric manifestations.

## Pediatric Clinical Chemistry

**Abstract:** Pediatric clinical chemistry involves specialized techniques and considerations due to the physiological differences between children and adults. This field plays a crucial role in diagnosing and managing various pediatric disorders, such as congenital hypothyroidism, cystic fibrosis, and type 1 diabetes mellitus. This chapter outlines the biochemical underpinnings of common pediatric diseases, discusses the appropriate laboratory tests and their interpretation, and addresses the challenges of using pediatric reference ranges. Understanding these aspects is essential for accurate diagnosis and effective management, ultimately improving patient outcomes.

**Keywords:** Clinical laboratory, Diagnosis, Management, Pediatric, Reference range.

### LEARNING OBJECTIVES

After reading this chapter, one should be able to:

- Discuss special considerations in relation to the provision of a general pediatric clinical laboratory service.
- Discuss the causes, clinical signs, and symptoms of the conditions that may present in a general pediatric laboratory.
- Describe which laboratory investigations are important in their detection, diagnosis, and management.
- Discuss specific laboratory investigations for the evaluation of disorders presenting in the neonate and in childhood.
- Recognize the analytical methods available for their measurement.
- Select laboratory investigations and interpret the analytical results in the context of clinical signs and symptoms.
- Recognize the importance of blood volume limitations in method selection.
- Recognize that the population-based reference intervals for many chemistry tests change throughout childhood.
- Discuss the importance of and challenges associated with determining pediatric reference intervals.

**KEY CONCEPTS****Key Concepts in General Pediatric Clinical Laboratory Service*****Special Considerations in Relation to the Provision of a General Pediatric Clinical Laboratory Service (Table 1)*****Table 1. Concept of general pediatric clinical laboratory service.**

<b>Key Concept</b>	<b>Details</b>
<b>Collection of Heel Stick Samples</b>	<ul style="list-style-type: none"> <li>-<b>Definition:</b> A minimally invasive blood collection method typically used for newborns and infants.</li> <li>-<b>Procedure:</b> Involves making a small puncture in the infant's heel to collect a few drops of blood.</li> <li>-<b>Uses:</b> Common for newborn screening tests, glucose monitoring, and bilirubin levels.</li> </ul>
<b>Issues with Capillary Specimens</b>	<ul style="list-style-type: none"> <li>-<b>Contamination Risk:</b> Capillary samples are prone to contamination with interstitial and intracellular fluids.</li> <li>-<b>Hemolysis:</b> Increased risk due to the small volume and handling techniques.</li> <li>-<b>Inconsistent Results:</b> Variability in blood flow and sample collection technique can lead to inconsistencies.</li> </ul>
<b>Pediatric Reference Intervals</b>	<ul style="list-style-type: none"> <li>-<b>Definition:</b> Age-appropriate reference ranges for interpreting laboratory results in pediatric populations.</li> <li>-<b>Importance:</b> Essential for accurate diagnosis and treatment, as children have different normal ranges than adults.</li> <li>-<b>Dynamic Changes:</b> Influenced by growth, development, and puberty stages.</li> </ul>
<b>Dynamic Changes with Growth, Development, and Puberty</b>	<ul style="list-style-type: none"> <li>-<b>Metabolic Rate Variability:</b> Changes in metabolism, hormone levels, and organ function as children grow.</li> <li>-<b>Impact on Lab Values:</b> Parameters such as hemoglobin, liver enzymes, and hormone levels vary significantly with age and developmental stage.</li> <li>-<b>Monitoring:</b> Requires age-specific reference intervals.</li> </ul>
<b>Challenges with Determining Pediatric Reference Intervals</b>	<ul style="list-style-type: none"> <li>-<b>Limited Data:</b> Fewer studies available compared to adult populations.</li> <li>-<b>Ethical Issues:</b> Concerns with obtaining blood samples from healthy children.</li> <li>-<b>Variability:</b> Differences in age, gender, ethnicity, and nutritional status make standardization difficult.</li> <li>-<b>Cost:</b> High costs of establishing and validating intervals.</li> </ul>

(Table 1) cont....

Key Concept	Details
Sample Volume and Collection Issues	<p><b>-Volume Constraints:</b> Pediatric patients have limited blood volume, necessitating minimal sample sizes.</p> <p><b>-Techniques:</b> Use of micro-collection tubes, capillary sticks, and minimizing the number of tests.</p> <p><b>-Pain and Stress:</b> Techniques that reduce pain and stress are essential for compliance and accuracy.</p>
Sweat Collection	<p><b>-Purpose:</b> Commonly used for cystic fibrosis screening by measuring chloride levels in sweat.</p> <p><b>-Procedure:</b> Involves stimulating sweat glands (typically on the forearm) and collecting sweat using specialized collection devices.</p> <p><b>-Challenges:</b> Small sample volume, variability in sweat production, and technical difficulties.</p>

## DISEASES

### Biochemical Basis, Relevant Lab Tests, Interpretation of Results, and Applied Aspects for

#### *Laboratory Investigations in Detection, Diagnosis and Management of Disorders Presenting in the Neonate and in Childhood (Table 2) [1 - 4]*

Table 2. Biochemical basis, relevant lab tests, interpretation of results, and applied aspects of disorders of neonate and childhood.

Condition	Biochemical Basis	Relevant Lab Tests	Interpretation of Results
1. Congenital Thyroid Disease	Deficiency or absence of thyroid hormones due to congenital thyroid gland abnormalities.	TSH, Free T4, T3, Thyroid ultrasound, Genetic testing	Elevated TSH with low Free T4 indicates congenital hypothyroidism. Thyroid ultrasound helps in anatomical assessment.
2. Cystic Fibrosis	A genetic disorder caused by mutations in the CFTR gene, affecting chloride channels.	Sweat chloride test, Genetic testing, Immunoreactive Trypsinogen (IRT) Test	Elevated sweat chloride levels confirm cystic fibrosis. Genetic testing identifies CFTR mutations.
3. Delayed Puberty	Hormonal imbalances, including gonadotropin deficiency or resistance.	LH, FSH, Estradiol (females), Testosterone (males), and Bone age assessment	Low LH/FSH levels suggest hypogonadotropic hypogonadism. Elevated LH/FSH with low sex steroids indicates gonadal failure.

## **Pregnancy and Prenatal Diagnosis**

**Abstract:** Pregnancy and prenatal diagnosis encompass a range of biochemical and molecular changes that are critical for maternal and fetal health. This chapter reviews the biochemical markers and diagnostic techniques utilized in monitoring pregnancy and diagnosing prenatal conditions. It covers the role of hormones, proteins, and other biomarkers in assessing the health of the mother and fetus. Additionally, the chapter explores various prenatal diagnostic techniques, including Non-Invasive Prenatal Testing (NIPT), ultrasound, and amniocentesis, highlighting their importance in detecting genetic and chromosomal abnormalities. The integration of advanced molecular diagnostics and clinical chemistry is crucial for effective prenatal care and improved pregnancy outcomes.

### **LEARNING OBJECTIVES**

After reading this chapter, one should be able to:

- Describe the following concepts about laboratory medicine support during pregnancy and related to the health of the mother and fetus.
- Describe the causes, clinical signs, and symptoms of the complications of pregnancy and fetal development.
- Describe the laboratory investigations that are important in their detection, diagnosis, and management.
- Describe specific laboratory investigations important to the study of pregnancy and fetal development.
- Recognize the analytical methods available for their measurement.
- Select laboratory investigations and interpret the analytical results in the context of clinical signs and symptoms.
- Discuss the clinical rationale for tests using amniotic fluid.

**KEY CONCEPTS****Key Concepts and Applied Aspects of Laboratory Medicine Support Related to Maternal and Fetal Health During Pregnancy*****Laboratory Medicine Support Related to the Health of the Mother and Fetus During Pregnancy (Table 1)*****Table 1. Laboratory medicine support related to the health of the mother and fetus during pregnancy.**

<b>Key Concepts</b>	<b>Description</b>	<b>Applied Aspects</b>
<b>Biochemical Changes</b>	Pregnancy induces hormonal and metabolic changes, including increases in human Chorionic Gonadotropin (hCG), estrogen, and progesterone.	Monitoring hormone levels ( <i>e.g.</i> , hCG, progesterone) for pregnancy confirmation, ectopic pregnancy, and miscarriage risk.
<b>Hematological Changes</b>	Pregnancy leads to physiological anemia due to increased plasma volume and hemodilution.	Complete Blood Count (CBC) to monitor hemoglobin levels, red cell mass, and identify anemia; iron supplementation if necessary.
<b>Endocrine Changes</b>	Endocrine adaptations include altered thyroid function and increased insulin resistance.	Thyroid function tests (T3, T4, TSH) to monitor maternal thyroid status; glucose tolerance tests to screen for gestational diabetes.
<b>Prenatal Screening and Diagnosis</b>	Involves biochemical markers ( <i>e.g.</i> , PAPP-A, free $\beta$ -hCG), ultrasound, and genetic testing for assessing fetal abnormalities.	First-trimester screening, Non-Invasive Prenatal Testing (NIPT) for Down syndrome, trisomy 18, and trisomy 13; amniocentesis and Chorionic Villus Sampling (CVS) for diagnosis.
<b>Monitoring Maternal Health</b>	Regular monitoring to detect and manage conditions like gestational diabetes, preeclampsia, and infections.	Blood pressure measurement, urine protein testing, glucose screening, and monitoring of infection markers ( <i>e.g.</i> , TORCH panel).
<b>Monitoring Fetal Health</b>	Assessment of fetal growth, development, and well-being through biochemical and imaging methods.	Ultrasound for fetal growth and anatomy; Doppler studies for placental blood flow; fetal heart rate monitoring; amniotic fluid analysis.
<b>Immunological Changes</b>	Pregnancy involves modulation of the maternal immune system to prevent fetal rejection and manage immune responses.	Monitoring of immune markers ( <i>e.g.</i> , IL-10, TNF- $\alpha$ ) to understand immune tolerance mechanisms; RhD antibody testing in Rh-negative mothers.
<b>Nutritional Status</b>	Nutritional demands increase during pregnancy, requiring adequate intake of vitamins and minerals.	Monitoring of vitamin D, calcium, folate, and iron levels; supplementation as required to prevent deficiencies and ensure fetal development.

(Table 1) cont....

Key Concepts	Description	Applied Aspects
<b>Infectious Disease Screening</b>	Screening for infections that can affect pregnancy outcomes, such as rubella, HIV, syphilis, and hepatitis.	Routine testing for Sexually Transmitted Infections (STIs) and other pathogens during early pregnancy to prevent transmission to the fetus.
<b>Postpartum Monitoring</b>	Assessment of maternal recovery and infant health following delivery.	Monitoring for postpartum anemia, thyroid function changes, and lactation issues; newborn screening for metabolic and genetic disorders.

## Laboratory Tests During Pregnancy

### Laboratory Investigations for Complications of Pregnancy and Fetal Development (Table 2 - 6)

Table 2. Laboratory investigations for complications of pregnancy and fetal development.

Test	Purpose	Analytical Methods	Interpretation
Complete Blood Count (CBC)	Monitor anemia, infection, and clotting status	Automated hematology analyzers	Low Hb: anemia; High WBC: infection; Platelets: clotting status
Glucose Tolerance Test (GTT)	Screen for gestational diabetes	Oral Glucose Tolerance Test (OGTT)	High glucose levels indicate gestational diabetes
Thyroid Function Tests (TSH, Free T4)	Monitor thyroid status	Immunoassays	High TSH: hypothyroidism; Low TSH: hyperthyroidism
Urinalysis	Screen for urinary tract infections, proteinuria	Dipstick analysis and microscopy	Proteinuria: preeclampsia; Bacteriuria: UTI
Liver Function Tests (ALT, AST, ALP)	Assess liver function	Enzymatic assays	Elevated levels may indicate liver dysfunction
Serum Electrolytes	Monitor electrolyte balance	Ion-Selective Electrodes (ISE)	Imbalances may indicate hyperemesis, preeclampsia
Hepatitis B Surface Antigen (HBsAg)	Screen for hepatitis B infection	Enzyme-linked immunosorbent assay	Positive: Hepatitis B infection
Rubella IgG	Assess immunity to rubella	Immunoassays	Positive: immunity; Negative: susceptible
HIV Antibody	Screen for HIV infection	ELISA and Western blot	Positive: HIV infection
Group B Streptococcus (GBS) Culture	Screen for GBS infection in late pregnancy	Culture methods	Positive: GBS colonization

## Therapeutic Drug Monitoring and Toxicology

**Abstract:** Therapeutic Drug Monitoring (TDM) and toxicology are essential for personalized medicine, ensuring safe and effective medication use while minimizing toxicity. TDM involves measuring drug concentrations in the blood to optimize dosage, especially for drugs with narrow therapeutic windows. Toxicology focuses on identifying, managing, and preventing the toxic effects of drugs and chemicals. This chapter highlights the practical aspects of TDM and toxicology, emphasizing their importance in clinical decision-making and addressing future challenges and directions in these fields.

**Keywords:** Drug measurement, Pharmacodynamics, Pharmacokinetics, Therapeutic drug monitoring, Toxicology.

### LEARNING OBJECTIVES

After going through this chapter, one should be able to:

- Describe key concepts of pharmacology and key factors relevant to drug action and measurement.
- Describe the mode of action and clinical uses of drugs in the categories listed as Pharmacokinetics (PK), Pharmacodynamics (PD), and Pharmacogenetics (PG).
- Describe the specific laboratory investigations and concepts important to therapeutic drug monitoring and toxicology.
- Recognize the analytical methods available for their measurement.
- Select laboratory investigations and interpret the analytical results in the context of clinical signs and symptoms.

**KEY CONCEPTS****Key Concepts of Pharmacology: Mode of Action and Clinical Uses of a Drug, Drug Action, and Measurement*****Pharmacology and Key Factors Relevant to Drug Action and Measurement (Table 1)*****Table 1. Drug action, its measurement, and applied aspects.**

<b>Key Concept</b>	<b>Details</b>	<b>Applied Aspects</b>
<b>Mode of Action of Drugs</b>	Mechanism by which drugs exert their effects on the body at the molecular, cellular, or organ level.	<ul style="list-style-type: none"> <li>- Understanding allows for targeted therapy</li> <li>- Basis for drug development and optimization.</li> </ul>
<b>Clinical Uses of Drugs</b>	Therapeutic applications of drugs to treat diseases and conditions.	<ul style="list-style-type: none"> <li>- Application in disease management and patient</li> <li>- Guiding treatment protocols and guidelines.</li> </ul>
<b>Drug Action</b>	Biochemical and physiological effects of drugs on the body.	<ul style="list-style-type: none"> <li>- Studying drug interactions and side effects</li> <li>- Optimizing dosage and administration regimens.</li> </ul>
<b>Measurement of Drug Action</b>	Quantification of drug effects in biological systems.	<ul style="list-style-type: none"> <li>- Pharmacokinetic and pharmacodynamic studies</li> <li>- Monitoring drug levels to ensure therapeutic efficacy.</li> </ul>

**Biochemical Basis, Relevant Lab Tests, Interpretation of Results, and Applied Aspects for*****Laboratory Investigations, Analytical Methods and Interpretation of Analytical Results (Table 2) [1-3]***

**Table 2. Biochemical basis, relevant lab tests, analytical methods, and interpretation of results.**

Category	Key Concepts	Applied Aspects
<b>Therapeutic Drug Monitoring (TDM)</b>	<i>Biochemical Basis</i>	
	Pharmacokinetics	Absorption, distribution, metabolism, and excretion of drugs
	Pharmacodynamics	Drug effects and mechanisms of action
	Therapeutic Range	Effective concentration range without toxicity
	Half-Life	Time required for the drug concentration to decrease by half
	Bioavailability	Proportion of the drug entering circulation to have an active effect
	<i>Analytical Methods</i>	
	High-Performance Liquid Chromatography (HPLC)	Separates and quantifies drug components
	Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)	Sensitive and specific for low drug concentrations
	Immunoassays	ELISA, RIA, fluorescence polarization immunoassay
	Gas Chromatography-Mass Spectrometry (GC-MS)	Used for volatile and non-volatile drugs
	Capillary Electrophoresis (CE)	Separation based on charge and size of molecules
	<i>Interpretation of Results</i>	
	Major Drug Classes	Anticonvulsants, antibiotics, immunosuppressants, anticoagulants, and cardiac drugs
	Rationale for TDM	Narrow therapeutic index, patient variability, drug interactions, compliance, and disease states
	Free vs. Total Drug Levels	Free drug is biologically active; relevant in altered protein binding
	<i>Interpretive Guidelines</i> Examples:	<i>Therapeutic ranges and cutoffs for specific drugs</i>
	Phenytoin	Therapeutic range: 10-20 µg/mL, Toxicity > 20 µg/mL
	Vancomycin	Trough level: 10-20 µg/mL, higher for severe infections
	Tacrolimus	Therapeutic range: 5-20 ng/mL depending on transplant type
Warfarin (INR)	Target INR: 2.0-3.0	

## Vitamins and Trace Elements

**Abstract:** Vitamins and trace elements play crucial roles in maintaining human health by actively participating in various metabolic processes. These micronutrients are indispensable for enzyme function, antioxidant defence, and immune system support. Deficiencies or excesses of these micronutrients can lead to a wide range of health issues, including anemia, immune dysfunction, and neurological disorders. This article thoroughly explores the practical applications of vitamins and trace elements, emphasizing their biochemical roles, clinical implications, and the interpretation of relevant laboratory tests. It provides a comprehensive overview of the diagnostic challenges and management strategies associated with micronutrient imbalances.

### LEARNING OBJECTIVES

After reading this chapter, one should be able to:

- Describe the importance of trace elements and vitamins to metabolic processes and well-being, the mechanisms of their actions, and the consequences of deficiency and overload states.
- Describe the causes, clinical signs, and symptoms of the following aspects of disorders of trace element and vitamin metabolism.
- Describe which laboratory investigations are important in their detection, diagnosis and management.
- Describe the following specific laboratory investigations important to the study of trace elements and vitamins.
- Recognize analytical methods available for their measurement.
- Select laboratory investigations and interpret the analytical results in the context of clinical signs and symptoms.

**KEY CONCEPTS****Key Concepts and Applied Aspects of Trace Elements and Vitamins*****Trace Elements and Vitamins: Mechanisms of Actions and the Consequences of Deficiency and Overload States (Table 1) [1, 2]*****Table 1.** Trace elements and vitamins: applied aspects.

<b>Category</b>	<b>Key Concepts</b>	<b>Applied Aspects</b>
<b>Trace Elements</b>	<b>Importance and Functions</b>	<b>Clinical Relevance and Applications</b>
	Iron (Fe)	Essential for hemoglobin, myoglobin, and enzyme function
	Zinc (Zn)	Important for immune function, enzyme activation, and DNA synthesis
	Copper (Cu)	Cofactor for enzymes involved in energy production and neurotransmitter synthesis
	Selenium (Se)	Component of antioxidant enzymes (glutathione peroxidase), thyroid hormone metabolism
	Iodine (I)	Crucial for thyroid hormone synthesis and regulation of metabolism
	Manganese (Mn)	An enzyme cofactor in the metabolism of amino acids, cholesterol, glucose, and carbohydrates
	Chromium (Cr)	Enhances insulin action, involved in carbohydrate, fat, and protein metabolism
	Molybdenum (Mo)	Cofactor for enzymes in sulfur amino acid, purine, and pyrimidine metabolism
	<b>Mechanisms of Action</b>	
	Cofactor Functions	Many trace elements act as cofactors for enzymes, enhancing catalytic activity
	Antioxidant Roles	Selenium and zinc are critical for antioxidant defense systems
	Hormone Synthesis	Iodine is essential for thyroid hormone production, and iron is important for erythropoiesis
	Immune Function	Zinc, selenium, and copper are vital for maintaining a healthy immune system

(Table 1) cont....

Category	Key Concepts	Applied Aspects
<b>Vitamins</b>	<b>Importance and Functions</b>	<b>Clinical Relevance and Applications</b>
	Vitamin A (Retinol)	Essential for vision, immune function, and cell growth
	Vitamin B1 (Thiamine)	Coenzyme in carbohydrate metabolism and nerve function
	Vitamin B2 (Riboflavin)	Part of the coenzymes involved in energy production and cellular function
	Vitamin B3 (Niacin)	Involved in DNA repair, energy production, and cellular metabolism
	Vitamin B5 (Pantothenic Acid)	Coenzyme in fatty acid metabolism and synthesis of coenzyme A
	Vitamin B6 (Pyridoxine)	Cofactor in amino acid metabolism, neurotransmitter synthesis, and hemoglobin production
	Vitamin B7 (Biotin)	Coenzyme in the metabolism of fatty acids, amino acids, and glucose
	Vitamin B9 (Folate)	Critical for DNA synthesis and repair, important in pregnancy for fetal development
	Vitamin B12 (Cobalamin)	Essential for red blood cell formation, neurological function, and DNA synthesis
	Vitamin C (Ascorbic Acid)	Antioxidant, important for collagen synthesis, immune function, and absorption of non-heme iron
	Vitamin D (Calciferol)	Regulates calcium and phosphate metabolism, crucial for bone health
	Vitamin E (Tocopherol)	Antioxidant and protects cell membranes from oxidative damage
	Vitamin K	Essential for blood clotting and bone metabolism
	<b>Mechanisms of Action</b>	
	Coenzyme Roles	Many vitamins function as coenzymes in metabolic reactions (e.g., B vitamins in energy metabolism)
	Antioxidant Activity	Vitamins C and E protect cells from oxidative stress
	Hormone-Like Functions	Vitamin D acts like a hormone in calcium and phosphorus homeostasis
	Gene Expression Regulation	Vitamins A and D regulate gene expression
	Immune Function	Vitamins A, C, D, and E play roles in maintaining and regulating the immune system

**SUBJECT INDEX****A**

Acid-base disturbances 20, 26, 32, 141  
Acidosis 3, 5, 6, 9, 11, 15, 17, 27, 28, 29, 100  
Acute 58, 68, 69, 70, 71, 72, 90, 91, 118, 123, 125, 142, 149  
    coronary syndrome (ACS) 58, 68, 69, 70, 71, 72, 90, 91  
    kidney injury (AKI) 118, 123, 125, 142, 149  
Adrenocorticotrophic hormone (ACTH) 128, 129, 131, 133, 134, 259  
Alpha-fetoprotein (AFP) 34, 39, 41, 48, 166, 171, 267, 269, 271, 273, 275, 276  
Aminolevulinic acid (ALA) 206, 208, 209, 211, 212, 248, 250, 293  
Albuminuria 74, 123  
Aldosterone 109, 110, 128, 129, 134, 139, 142, 145, 146, 149  
Alkalosis 3, 5, 7, 9, 15, 17, 28, 31, 148  
Alkaline phosphatase (ALP) 49, 166, 168, 170, 171, 184, 186, 230, 231, 232, 233, 234, 244  
Alanine transaminase (ALT) 50, 123, 166, 169, 170, 171, 184, 186, 265, 269  
Antidiuretic hormone (ADH) 20, 110, 130, 132, 134, 139, 142, 145, 146, 147, 148  
Anti-neutrophil cytoplasmic antibodies (ANCA) 124, 125, 184, 186, 238, 240, 242  
Apolipoprotein 73, 77, 78, 218, 219, 221, 224  
Atherosclerosis 69, 70, 71, 76, 77, 78, 84, 85, 86, 87, 215, 218, 220, 221

Aspartate transaminase (AST) 50, 123, 166, 169, 170, 171, 184, 186, 237, 265, 269

**B**

Bicarbonate 2, 3, 6, 7, 8, 9, 115, 119, 139, 152, 154  
Bilirubin 50, 165, 166, 169, 170, 171, 184, 186, 206, 208, 269  
Biliverdin 165, 206, 208  
Blood urea nitrogen (BUN) 80, 82, 114, 115, 119, 120, 121, 122, 125, 142, 143, 146, 147, 148

**C**

Calcitonin 54, 139, 231, 233  
Calcitriol 110, 230, 231  
Cell-free DNA (cfDNA) 47, 65, 66, 273, 275  
Cerebrospinal fluid (CSF) 16, 246, 251, 254  
Ceruloplasmin 171, 186, 206, 292, 293  
Chylomicrons 153, 216, 218, 220, 226, 227  
Chronic kidney disease (CKD) 108, 116, 123, 125, 126, 142, 149, 230, 234  
Creatine kinase (CK) 71, 75, 84, 91, 237, 239, 243  
Creatinine 80, 82, 109, 110, 116, 118, 119, 120, 122, 125, 143, 146, 147, 148  
Central venous pressure (CVP) 142, 143, 144

**D**

Diabetes insipidus 130, 132, 134, 142, 146, 147, 149

Diabetic ketoacidosis (DKA) 15, 20, 26,  
31, 94, 97, 98, 99, 101, 102,  
104  
Dyslipidemia 77, 81, 82, 84, 85, 87, 98,  
100, 217, 220, 222, 225, 226

**E**

Estimated glomerular filtration rate (eGFR)  
115, 119, 121, 124  
Enzyme-linked immunosorbent assay  
(ELISA) 89, 101, 102, 120, 134, 135,  
158, 159, 160, 161, 186,  
187, 188, 200, 202, 203,  
234, 241, 242, 250  
Erythropoietin 110

**F**

Follicle stimulating hormone (FSH) 135,  
258, 260

**G**

Gas chromatography 26, 186, 195, 280,  
281, 285  
(GC) 26, 186, 285  
mass spectrometry (GC-MS) 195,  
280, 281  
Gestational diabetes mellitus (GDM) 97,  
98, 100, 102, 104, 264, 265,  
266, 267, 268  
Gluconeogenesis 95, 96, 110, 153  
Glucose tolerance test (GTT) 96, 102,  
265, 266  
Glutathione peroxidase (GPx) 72, 76,  
288  
Glycated hemoglobin (HbA1c) 73, 78,  
81, 96, 97, 98, 99, 100, 101,  
102, 104, 259, 268  
Glycogenesis 95, 153, 165  
Glycogenolysis 95, 153, 165

Growth hormone (GH) 35, 95, 128, 129,  
131, 133, 135, 259

**H**

High-density lipoprotein (HDL) 71, 75,  
77, 78, 81, 216, 217, 218,  
219, 220, 221, 222, 225, 226  
Human chorionic gonadotropin (hCG)  
34, 39, 42, 56, 264, 266,  
275, 276  
High-sensitivity C-reactive protein (hsCRP)  
73, 74, 78, 85, 87, 221, 225  
Hyperaldosteronism 27, 130, 132, 142,  
146  
Hyperbilirubinemia 166, 171  
Hypercalcemia 35, 54, 61, 140, 229,  
231, 234, 290, 291  
Hyperglycemia 35, 72, 76, 84, 96, 98,  
99, 100, 104, 153, 268  
Hyperkalemia 138, 140, 141, 144, 146,  
147, 148, 150, 239  
Hypernatremia 140, 141, 144, 146, 147,  
148, 150  
Hyperparathyroidism 61, 136, 230, 231,  
233, 234  
Hypertension 82, 146, 149  
Hyperthyroidism 57, 131, 133, 135, 222,  
261, 265, 267  
Hypertriglyceridemia 156, 218, 227  
Hypervitaminosis 291, 292, 295  
Hypocalcemia 140, 156, 229, 232, 234,  
259, 260, 262  
Hypoglycemia 99, 100, 102, 104, 153,  
157, 193  
Hypokalemia 27, 28, 130, 132, 140, 141,  
144, 146, 147, 148, 232  
Hypomagnesemia 229, 232, 234  
Hyponatremia 131, 133, 138, 140, 144,  
146, 147, 148, 150  
Hypoparathyroidism 230, 231, 232, 234,  
259

Hypophosphatemia 232, 234  
Hypotension 112, 130, 131, 132, 133,  
142, 143, 146  
Hypothyroidism 130, 131, 132, 133,  
135, 221, 258, 261, 265,  
267, 290  
Hypoventilation 15, 17, 27, 30  
Hypovolemia 141, 143, 144

**I**

Inborn errors of metabolism (IEM) 190,  
191  
Immunoglobulins 61, 89, 90, 176, 177,  
182, 185, 270, 274  
Immunohistochemistry (IHC) 39, 42, 43,  
44, 45, 46, 251  
Immunosuppressants 114, 249, 280, 283,  
284  
Ion-selective electrodes (ISE) 13, 28,  
101, 119, 121, 123, 149,  
185, 234, 260, 265

**L**

Lactate dehydrogenase (LDH) 58, 210,  
237, 270  
Low-density lipoprotein (LDL) 71, 73,  
75, 77, 216, 217, 218, 219,  
220, 221, 222, 225, 226  
Lipase 153, 154, 155, 156, 159, 161, 216  
Lipolysis 95, 99, 216  
Liver function tests (LFTs) 44, 49, 50,  
51, 52, 80, 84, 86, 88, 166,  
170, 172, 269, 270

**M**

Mass spectrometry (MS) 46, 120, 123,  
149, 192, 194, 195, 250,  
251, 253, 260, 261, 280,  
281, 285

Microscopic examination 44, 119, 121,  
200, 274  
Myocardial infarction (MI) 68, 71, 72,  
75, 76, 83, 84, 85, 90, 91,  
92, 243

**N**

Non-invasive prenatal testing 263, 264,  
267, 270, 273, 275, 276

**O**

Oral glucose tolerance test (OGTT) 99,  
100, 101, 102, 135, 265,  
267, 268  
Osmolality 18, 19, 31, 99, 100, 139, 146,  
147, 148, 149  
Osmolar gap 18, 19, 20, 31  
Osmolarity 18, 19  
Osteomalacia 49, 230, 233, 234, 244,  
290, 291  
Osteoporosis 49, 229, 233, 234, 235,  
243, 244

**P**

Parathyroid hormone (PTH) 35, 109,  
116, 120, 139, 229, 230,  
231, 232, 233, 234  
Plasma renin activity (PRA) 145, 146,  
149  
Polymerase chain reaction (PCR) 36, 45,  
46, 184, 187, 194, 198, 200,  
202, 203, 224  
Porphyrias 205, 208, 209, 211, 212, 213,  
214, 248, 253, 293  
Preeclampsia 264, 265, 267  
Prostate-specific antigen (PSA) 34, 36,  
39, 42, 43, 45, 60  
Proteinuria 81, 82, 116, 124, 265, 269,  
270

Prothrombin time (PT) 166, 168, 170, 266, 291

**Q**

Quality control 192  
Quantitative analysis 43, 47

**R**

Radioimmunoassay (RIA) 46, 101, 102, 134, 135, 250, 253, 260, 261, 280, 285  
Renal 26, 30, 31, 44, 73, 80, 82, 84, 86, 88, 91, 99, 100, 108, 109, 110, 111, 115, 119, 121, 122, 124, 125, 139, 140, 141, 142, 148, 149, 231, 232, 233, 239  
    biopsy 115, 119  
    failure 26, 30, 31, 91, 125, 140, 148, 231, 232, 233  
    function 80, 82, 99, 100, 108, 109, 110, 111, 139, 141, 142, 232, 239  
    function markers 73, 124  
    function tests 44, 82, 84, 86, 88, 121, 122, 149, 239  
Renin 82, 109, 110, 124, 128, 129, 134, 142, 145, 146  
    levels 82, 124, 134  
Resistance 65, 198, 201, 232, 258, 268, 282  
Risk 60, 68, 71, 73, 74, 75, 77, 78, 81, 82, 84, 85, 86, 87, 92, 98, 116, 218, 219, 221, 223, 224, 225, 273, 275  
    assessment 74, 92, 224, 225, 273, 275  
    factors 60, 68, 71, 73, 75, 77, 78, 81, 82, 84, 85, 86, 87, 98,

116, 218, 219, 221, 223  
calculators 74, 219

**S**

Safety 111, 113, 283, 284, 285, 292  
Salicylate 14, 31  
    poisoning 31  
Samples 39, 134, 191, 199, 262  
Sample collection 40, 191, 192, 257, 262  
Screening 36, 39, 40, 41, 99, 104, 105, 121, 158, 161, 171, 186, 191, 192, 219, 242, 248, 251, 253, 265, 266, 267, 270, 271, 273, 275, 281, 285  
    tests 158, 161, 192, 237, 240, 242, 257, 267, 272, 276  
Secretion 34, 109, 127, 139, 146, 152, 153, 154, 166, 218  
Seizures 131, 133, 142, 144, 281, 283, 284  
Sensitivity 40, 41, 45, 46, 64, 123, 186, 187, 199, 200, 237, 240  
Serology 169, 170, 197, 198, 203  
    tests 198, 199, 200  
Serum 1, 14, 19, 26, 27, 28, 29, 30, 31, 34, 39, 44, 49, 61, 78, 79, 80, 81, 82, 83, 89, 90, 98, 99, 100, 115, 116, 119, 121, 122, 123, 124, 125, 131, 133, 134, 135, 141, 142, 143, 144, 146, 147, 148, 149, 150, 159, 161, 166, 170, 171, 183, 184, 185, 188, 208, 210, 212, 222, 231, 232, 233, 243, 247, 250, 251, 252, 253, 256, 257, 258, 259, 261, 264, 266, 268, 269, 275, 283, 291, 292, 293, 294, 295  
    creatinine 78, 115, 116, 119, 121, 122, 123, 124, 125, 184

electrolytes 28, 29, 31, 116, 119, 123, 143, 144, 146, 147, 148  
Severity 31, 76, 86, 87, 88, 92, 115, 201, 238  
Signs 57, 62, 70, 83, 85, 86, 88, 143, 146, 147, 148, 166, 274  
Skin turgor 141, 143, 146  
Systemic lupus erythematosus (SLE) 125, 186, 187, 237, 238, 240, 241, 242  
Sodium 80, 109, 110, 112, 114, 115, 128, 129, 139, 145, 146, 147, 148, 149  
    levels 110, 145  
Solutions 1, 17, 18  
Specificity 40, 41, 45, 46, 48, 64, 84, 123, 177, 200, 237, 238, 240  
Spectrophotometry 119, 121, 122, 123, 171, 211, 253, 290, 293, 294  
Staging 43, 47, 48, 52  
Statins 98, 216, 217, 218, 220, 221, 222, 223, 227  
Steroids 130, 132, 258, 260  
Strategies 31, 38, 43, 138, 149, 195, 219, 225, 294  
Stress 35, 69, 70, 71, 74, 76, 80, 84, 86, 98, 128, 129, 131, 133, 147, 156, 210, 258, 261, 289  
Structure 115, 119, 177, 182, 237, 246, 266  
Substances 18, 19, 20, 31, 34, 35, 36, 109, 116, 120, 121, 139, 190, 246, 281, 283, 284, 285  
Supplementation 193, 194, 207, 231, 232, 233, 264, 269, 292, 295  
Surgery 113, 162, 231, 251, 269  
Surgical removal 63, 269  
Sweat chloride test 193, 258  
Symptoms 25, 31, 81, 97, 144, 157, 190, 208, 209, 212, 213, 241, 243, 290, 292

Syndrome 34, 62, 66, 124, 126, 130, 132, 146, 148, 149, 157, 219, 220, 221, 232, 242, 247, 269

## T

Therapeutic drug monitoring (TDM) 284  
Thyroid 63, 81, 82, 84, 86, 87, 131, 133, 135, 183, 192, 222, 258, 261, 264, 265, 267  
    function tests (TFTs) 63, 81, 82, 84, 86, 87, 183, 222, 264, 265, 267  
    stimulating hormone (TSH) 63, 131, 133, 135, 183, 192, 258, 261, 264, 265, 267  
Triglycerides 71, 73, 77, 81, 82, 85, 87, 216, 221, 222, 224, 225, 227  
Troponins 68, 71, 75, 83, 84, 90, 91, 92

## U

Urinary albumin-to-creatinine ratio (UACR) 83, 115, 119, 121, 122, 124  
Uric acid 34, 109, 110, 122, 123, 124, 252

## V

Very low-density lipoprotein (VLDL) 73, 77, 78, 216, 217, 218, 220, 226, 227  
Viral  
    culture 202  
    hepatitis 166, 171, 172, 238  
    load 169, 170, 202  
    replication 180  
    infections 62, 95, 97, 180, 199, 200

## **Simmi Kharb**

---

Dr. Simmi Kharb is a distinguished academician and Senior Professor of Biochemistry at Pt. B.D. Sharma Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, with a strong track record in teaching, research, and academic leadership. She has made substantial contributions to the field of biochemistry through the publication of more than 200 research papers in reputed indexed journals and has actively participated in the global scientific community by presenting over 70 papers at national and international conferences. An experienced mentor, Dr. Kharb has successfully guided 23 MD theses, fostering the development of future medical professionals and researchers.

In addition to her research accomplishments, she is a prolific author, having published several widely recognized books covering areas such as biochemistry, clinical chemistry, and scientific writing, including titles like Daily Practical Sheet in Biochemistry, Biochemistry Review with Clinical Correlations, and the Mind Maps series. She has also contributed chapters to numerous academic books, authored two specialized monographs, and developed study modules focused on scientific writing techniques, project management in biotechnology, and advances in computing. Dr. Kharb's work reflects her dedication to enhancing medical education, promoting research excellence, and bridging the gap between theoretical knowledge and clinical application.